<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Bupropion for attention deficit hyperactivity disorder (ADHD) in adults - Verbeeck, W - 2017 | Cochrane Library</title> <meta content="Bupropion for attention deficit hyperactivity disorder (ADHD) in adults - Verbeeck, W - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009504.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Bupropion for attention deficit hyperactivity disorder (ADHD) in adults - Verbeeck, W - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009504.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009504.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Bupropion for attention deficit hyperactivity disorder (ADHD) in adults" name="citation_title"/> <meta content="Wim Verbeeck" name="citation_author"/> <meta content="GGZ Vincent van Gogh Instituut Venray" name="citation_author_institution"/> <meta content="WVerbeeck@vvgi.nl" name="citation_author_email"/> <meta content="Geertruida E Bekkering" name="citation_author"/> <meta content="Belgian Centre for Evidence‐Based Medicine ‐ Cochrane Belgium" name="citation_author_institution"/> <meta content="Wim Van den Noortgate" name="citation_author"/> <meta content="Katholieke Universiteit Leuven" name="citation_author_institution"/> <meta content="Cornelis Kramers" name="citation_author"/> <meta content="Radbound University Nijmegen Medical Center" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD009504.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/10/02" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009504.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009504.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009504.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Attention Deficit Disorder with Hyperactivity [*drug therapy]; Bupropion [administration &amp; dosage, adverse effects, *therapeutic use]; Central Nervous System Stimulants [administration &amp; dosage, adverse effects, *therapeutic use]; Delayed‐Action Preparations; Off‐Label Use; Patient Dropouts [statistics &amp; numerical data]; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009504.pub2&amp;doi=10.1002/14651858.CD009504.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009504.pub2&amp;doi=10.1002/14651858.CD009504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009504.pub2&amp;doi=10.1002/14651858.CD009504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009504.pub2&amp;doi=10.1002/14651858.CD009504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009504.pub2&amp;doi=10.1002/14651858.CD009504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009504.pub2&amp;doi=10.1002/14651858.CD009504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009504.pub2&amp;doi=10.1002/14651858.CD009504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009504.pub2&amp;doi=10.1002/14651858.CD009504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009504.pub2&amp;doi=10.1002/14651858.CD009504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009504.pub2&amp;doi=10.1002/14651858.CD009504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009504.pub2&amp;doi=10.1002/14651858.CD009504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009504.pub2&amp;doi=10.1002/14651858.CD009504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009504.pub2&amp;doi=10.1002/14651858.CD009504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009504.pub2&amp;doi=10.1002/14651858.CD009504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009504.pub2&amp;doi=10.1002/14651858.CD009504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009504.pub2&amp;doi=10.1002/14651858.CD009504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009504.pub2&amp;doi=10.1002/14651858.CD009504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009504.pub2&amp;doi=10.1002/14651858.CD009504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009504.pub2&amp;doi=10.1002/14651858.CD009504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009504.pub2&amp;doi=10.1002/14651858.CD009504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009504.pub2&amp;doi=10.1002/14651858.CD009504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009504.pub2&amp;doi=10.1002/14651858.CD009504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009504.pub2&amp;doi=10.1002/14651858.CD009504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="wbKFI7vu";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009504\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009504\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009504\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009504\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ru","ms","hr","fr","pl","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009504.pub2",title:"Bupropion for attention deficit hyperactivity disorder (ADHD) in adults",firstPublishedDate:"Oct 2, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Developmental, Psychosocial and Learning Problems Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=wbKFI7vu&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009504.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009504.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009504.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009504.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009504.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009504.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009504.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009504.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009504.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009504.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>36043 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009504.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009504.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009504.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009504.pub2/full#CD009504-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009504.pub2/full#CD009504-sec-0116"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009504.pub2/full#CD009504-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009504.pub2/full#CD009504-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009504.pub2/full#CD009504-sec-0037"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009504.pub2/full#CD009504-sec-0038"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009504.pub2/full#CD009504-sec-0071"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009504.pub2/full#CD009504-sec-0110"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009504.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009504.pub2/appendices#CD009504-sec-0121"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009504.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009504.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/table_n/CD009504StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/table_n/CD009504StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009504.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009504.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009504.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009504.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009504.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009504.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Bupropion for attention deficit hyperactivity disorder (ADHD) in adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009504.pub2/information#CD009504-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Wim Verbeeck</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009504.pub2/information#CD009504-cr-0003">Geertruida E Bekkering</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009504.pub2/information#CD009504-cr-0004">Wim Van den Noortgate</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009504.pub2/information#CD009504-cr-0005">Cornelis Kramers</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/information/en#CD009504-sec-0150">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 02 October 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009504.pub2">https://doi.org/10.1002/14651858.CD009504.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009504-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009504-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009504-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009504-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009504-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009504-abs-0015">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009504-abs-0001" lang="en"> <section id="CD009504-sec-0001"> <h3 class="title" id="CD009504-sec-0001">Background</h3> <p>Attention deficit hyperactivity disorder (ADHD) is a prevalent neurobiological condition, characterised by behavioral and cognitive symptoms such as inattention, impulsivity and/or excessive activity. The syndrome is commonly accompanied by psychiatric comorbidities and is associated with educational and occupational underachievement. </p> <p>Although psychostimulant medications are the mainstay of treatment for ADHD, not all adults respond optimally to, or can tolerate, these medicines. Thus, alternative non‐stimulant treatment approaches for ADHD have been explored. One of these alternatives is bupropion, an aminoketone antidepressant and non‐competitive antagonism of nicotinic acetylcholine receptors. Bupropion is registered for the treatment of depression and smoking cessation, but is also used off‐label to treat ADHD. </p> </section> <section id="CD009504-sec-0002"> <h3 class="title" id="CD009504-sec-0002">Objectives</h3> <p>To assess the effects and safety of bupropion for the treatment of adults with ADHD.</p> </section> <section id="CD009504-sec-0003"> <h3 class="title" id="CD009504-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and seven other databases in February 2017. We also searched three trials registers and three online theses portals. In addition, we checked references of included studies and contacted study authors to identify potentially relevant studies that were missed by our search. </p> </section> <section id="CD009504-sec-0004"> <h3 class="title" id="CD009504-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials (RCTs) that evaluated the effects (including adverse effects) of bupropion compared to placebo in adults with ADHD. </p> </section> <section id="CD009504-sec-0005"> <h3 class="title" id="CD009504-sec-0005">Data collection and analysis</h3> <p>Two review authors (WV, GB) independently screened records and extracted data using a data extraction sheet that we tested in a pilot study. We extracted all relevant data on study characteristics and results. We assessed risks of bias using the Cochrane 'Risk of bias' tool, and assessed the overall quality of evidence using the GRADE approach. We used a fixed‐effect model to pool the results across studies. </p> </section> <section id="CD009504-sec-0006"> <h3 class="title" id="CD009504-sec-0006">Main results</h3> <p>We included six studies with a total of 438 participants. Five studies were conducted in the USA, and one in Iran. All studies evaluated a long‐acting version of bupropion, with the dosage ranging from 150 mg up to 450 mg daily. Study intervention length varied from six to 10 weeks. Four studies explicitly excluded participants with psychiatric comorbidity and one study included only participants with opioid dependency. Four studies were funded by industry, but the impact of this on study results is unknown. Two studies were publicly funded and in one of these studies, the lead author was a consultant for several pharmaceutical companies and also received investigator‐driven funding from two companies, however none of these companies manufacture bupropion. We judged none of the studies to be free of bias because for most risk of bias domains the study reports failed to provide sufficient details. Using the GRADE approach, we rated the overall quality of evidence as low. We downgraded the quality of the evidence because of serious risk of bias and serious imprecision due to small sample sizes. </p> <p>We found low‐quality evidence that bupropion decreased the severity of ADHD symptoms (standardised mean difference ‐0.50, 95% confidence interval (CI) ‐0.86 to ‐0.15, 3 studies, 129 participants), and increased the proportion of participants achieving clinical improvement (risk ratio (RR) 1.50, 95% CI 1.13 to 1.99, 4 studies, 315 participants), and reporting an improvement on the Clinical Global Impression ‐ Improvement scale (RR 1.78, 95% CI 1.27 to 2.50, 5 studies, 337 participants). There was low‐quality evidence that the proportion of participants who withdrew due to any adverse effect was similar in the bupropion and placebo groups (RR 1.20, 95% CI 0.35 to 4.10, 3 studies, 253 participants). The results were very similar when using a random‐effects model and when we analysed only studies that excluded participants with a psychiatric comorbidity. </p> </section> <section id="CD009504-sec-0007"> <h3 class="title" id="CD009504-sec-0007">Authors' conclusions</h3> <p>The findings of this review, which compared bupropion to placebo for adult ADHD, indicate a possible benefit of bupropion. We found low‐quality evidence that bupropion decreased the severity of ADHD symptoms and moderately increased the proportion of participants achieving a significant clinical improvement in ADHD symptoms. Furthermore, we found low‐quality evidence that the tolerability of bupropion is similar to that of placebo. In the pharmacological treatment of adults with ADHD, extended‐ or sustained‐release bupropion may be an alternative to stimulants. The low‐quality evidence indicates uncertainty with respect to the pooled effect estimates. Further research is very likely to change these estimates. More research is needed to reach more definite conclusions as well as clarifying the optimal target population for this medicine. Treatment response remains to be reported in a DSM5‐diagnosed population. There is also a lack of knowledge on long‐term outcomes. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009504-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009504-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD009504-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD009504-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009504-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009504-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009504-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009504-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD009504-abs-0011">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009504-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009504-abs-0016">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD009504-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009504-abs-0004" lang="en"> <h3>Bupropion for attention deficit hyperactivity disorder (ADHD) in adults</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence on the effects of the drug bupropion in adults with ADHD. We also reviewed adverse effects (side effects experienced as a result of taking the drug). </p> <p><b>Background</b> </p> <p>ADHD is a brain disorder marked by an ongoing pattern of inattention, impulsivity and/or excessive activity, which interferes with functioning or development. Some people with ADHD only have problems with one of the behaviors, while others have a combination. Bupropion is a drug that is registered for the treatment of depression and for stopping smoking, but is also used to treat ADHD. People with ADHD are usually prescribed stimulant drugs such as methylphenidate and amphetamines. However, not everyone responds well to stimulants. Some people cannot tolerate stimulants because of side effects. Others have medical conditions such as psychiatric conditions or tic disorders that make it not possible to use stimulants. Other people may not want to use stimulants, as these are controlled substances. Nonstimulants such as bupropion are therefore sometimes used instead. Its effectiveness in treating ADHD is not yet known. </p> <p><b>Search date</b> </p> <p>The evidence is current to February 2017.</p> <p><b>Study characteristics</b> </p> <p>We included six randomised controlled trials (RCTs), that is, studies in which participants are randomly allocated to one of two or more treatment groups. Five of the studies took place in the USA, and the sixth in Iran. The studies included 438 people with ADHD. All evaluated a long‐acting version of bupropion, that is to say, a version of the drug is absorbed slowly, and can therefore be taken just once a day. This simple dosage suits people with ADHD, as the illness may make it difficult for them to remember to take their medication. </p> <p>The duration of the studies varied between six and 10 weeks. All participants were diagnosed with ADHD, and often had other mental health problems. In one study, all participants had ADHD and were addicted to opioids (a drug that relieves pain). </p> <p><b>Study funding sources</b> </p> <p>Four studies were funded by industry and two studies were publicly funded. In one of the publicly‐funded studies, the lead author was paid by industry (although not by the manufacturers of buproprion) for research activities. </p> <p><b>Key results</b> </p> <p>Bupropion may lead to a small improvement in ADHD and it may also decrease symptoms related to ADHD. The drug does not have more adverse effects than treatment with placebo. Bupropion may be an alternative treatment for adults with ADHD who cannot or will not take stimulant drugs. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence in this review is low, because we found very few studies; five of the six studies were small, and all were poorly conducted. The effect of bupropion on various aspects of daily functioning was not investigated. Also, no studies assessed the long‐term effects of this drug. Further studies are needed, to assess whether bupropion is effective in specific ADHD subgroups or in people who have additional disorders. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009504-sec-0116" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009504-sec-0116"></div> <h3 class="title" id="CD009504-sec-0117">Implications for practice</h3> <section id="CD009504-sec-0117"> <p>This review found suggestive evidence on the effectiveness of bupropion. Tolerability of bupropion appears similar to that of placebo. The quality was low, indicating uncertainty. Currently, guidance for practice can only be based on these data, which are limited in amount and in quality. Extended‐ or sustained‐release bupropion may be an alternative compound to stimulants in the pharmacological treatment of adults with ADHD. However, based on the evidence, prescribers may wish to exercise caution in the prolonged use of bupropion in ADHD, given the lack of studies that have assessed long‐term outcomes. Due to the limited number of studies, we can offer no guidance on sequential use after or instead of methylphenidate, or preferred use in participants with comorbid depression. In future, Research Domain Critera (RDoC; see below) may provide a means of reclassifying this population in ways that could prospectively differentiate bupropion responders from non‐responders, based on parameters that are not employed in clinical practice using current ADHD criteria. </p> </section> <h3 class="title" id="CD009504-sec-0118">Implications for research</h3> <section id="CD009504-sec-0118"> <p>First, a better understanding of the underlying pathophysiology of ADHD is necessary. A deeper insight into the different molecular subtypes of ADHD would inform us as to which group of medications would match a particular individual. Also, the underlying neurochemistry of ADHD and comorbid conditions, such as mood disorders, is very limited and warrants further preclinical research. </p> <p>Second, a new approach should be explored, aiming to reduce heterogeneity between studies of ADHD. Currently, inclusion in studies is typically based on behavioural criteria (top‐down paradigms). In 2013, the National Institute of Mental Health (NIMH) suggested re‐orienting away from the DSMs symptom‐based categories. They embarked on a new approach to psychiatric classification aimed at reflecting functional dimensions based on translational research on gene circuits and behaviour. The new framework is called RDoC, with broader research categories incorporating behavioural and neuroscience evidence (bottom‐up paradigm). The goal of RDoC is to relate fundamental domains of behavioural functioning to underlying neurobiological components, conceptualised as disorders in brain circuitry; the critical change is to a more empirically‐based system rather than grounded in symptom‐based diagnostic categories, which only constitute conventions between psychiatrists. According to <a href="./references#CD009504-bbs2-0042" title="FirstMB . Comments: The National Institute of Mental Health Research Domain Criteria (RDoC) project: moving towards a neuroscience‐based diagnostic classification in psychiatry. In: KendlerKS , ParnasJ editor(s). Philosophical Issues in Psychiatry II: Nosology. Oxford: Oxford University Press, 2013:12‐8. ">First 2013</a>, the RDoC approach represents a true paradigm shift in the classification of mental disorders, moving away from defining disorders based on descriptive phenomenology, to a focus on neural circuitry as the fundamental classificatory principle. He points out that RDoC's impact on future clinical classification in psychiatry will depend on how well the included molecular and neurobiological parameters predict prognosis and treatment response. </p> <p>In the meantime, the quality of trials could be improved by emphasising effectiveness outcomes, in contrast to efficacy outcomes. Also, future studies should assess potential cognitive benefits. Current clinical trials have strict exclusion criteria, and the extent to which these results apply to patients who, in routine practice, would have been excluded from participation in those trials is unclear. Trials could therefore include more 'naturalistic' participants with comorbid disorders that are highly prevalent amongst adults with ADHD, such as mood disorders and substance use disorders. Furthermore, more long‐term effectiveness studies are warranted, assessing the impact on the quality of life and ability to function in occupational, social and leisure spheres. They should include sufficient sample sizes, and make use of validated outcome measures. In addition, long‐term assessments of the safety of this drug are needed, because the pharmacological treatment of ADHD is usually chronic in nature. Finally, future head‐to‐head studies comparing efficacy and safety with approved agents, such as stimulants and atomoxetine, will benefit practice recommendations in this field. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009504-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009504-sec-0029"></div> <div class="table" id="CD009504-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Bupropion compared with placebo for adult ADHD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Participant or population:</b> Adults with ADHD </p> <p><b>Settings:</b> Ambulant care </p> <p><b>Intervention:</b> Bupropion </p> <p><b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Bupropion</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severity of ADHD (at study completion)</b> </p> <p>WRAADDS scale (0 to 28), ADHD‐RS scale (0 to 54) or CAARS scale (0 to 48). On all scales, a higher score equates to more symptoms </p> <p>(at 6 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score for severity of ADHD ranged across control groups from 14.70 (WRAADDS) to 23.80 (ADHD‐RS) and 34.43 (CAARS) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised mean score for severity of ADHD in the intervention groups was on average 0.50 <b>lower</b> (0.86 lower to 0.15 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Achievement of significant clinical improvement (% participants)</b> </p> <p>(at 6 to 10 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>212 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>318 per 1000</b> <br/> (from 240 to 422) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.50</b> (1.13 to 1.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>315<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CGI ‐ Improvement scale (% participants achieving at least 1 or 2 on CGI)</b> </p> <p>(at 6 to 10 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>395 per 1000</b> </p> <p>(from 282 to 555)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.78</b> (1.27 to 2.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>337<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants withdrawn due to adverse events</b> </p> <p>(at 6 to 10 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>73 per 1000</b> <br/> (from 21 to 250) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.20</b> (0.35 to 4.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> was the median control group risk across studies. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ADHD:</b> attention deficit hyperactivity disorder; <b>ADHD‐RS:</b> ADHD symptoms rating scale; <b>CAARS:</b> Conners' Adult ADHD Rating Scales; <b>CGI:</b> Clinical Global Impression scale;<b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; <b>WRAADDS:</b> Wender‐Reimherr Adult Attention Deficit Disorder Scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to limitations in study design. Most quality items were poorly reported.<br/> <sup>2</sup>Downagraded by one level due to imprecision. Optimal information size (OIS) not met. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009504-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009504-sec-0030"></div> <section id="CD009504-sec-0031"> <h3 class="title" id="CD009504-sec-0031">Description of the condition</h3> <p>Attention deficit hyperactivity disorder (ADHD) is a prevalent neurobiological condition, which persists throughout the lifespan, affecting an estimated 6% of adolescents and 3% to 4% of adults (<a href="./references#CD009504-bbs2-0040" title="FayyadJ , DeGraafR , KesslerR , AlonsoJ , AngermeyerM , DemyttenaereK , et al. Cross‐national prevalence and correlates of adult attention‐deficit hyperactivity disorder. British Journal of Psychiatry2007;190:402‐9. [DOI: 10.1192/bjp.bp.106.034389; PUBMED: 17470954] ">Fayyad 2007</a>). ADHD is characterised by problems of inattention, impulsivity and/or excessive activity, and is commonly associated with emotional instability, sleep problems, risk‐taking behaviour, accident proneness, delinquency, poor self‐esteem and co‐occurring mental illnesses such as mood, personality and substance use disorders (<a href="./references#CD009504-bbs2-0013" title="AshersonP . Clinical assessment and treatment of attention deficit hyperactivity disorder in adults. Expert Review of Neurotherapeutics2005;5(4):525‐39. [DOI: 10.1586/14737175.5.4.525; PUBMED: 16026236] ">Asherson 2005</a>). This kaleidoscopic scale of symptoms can culminate in substantial academic underachievement, as well as occupational, social and relational impairment (<a href="./references#CD009504-bbs2-0101" title="VaughanBS , WetzelMW , KratochvilCJ . Beyond the 'typical' patient: treating attention‐deficit/hyperactivity disorder in preschoolers and adults. International Review of Psychiatry2008;20(2):143‐9. [DOI: 10.1080/09540260801887751; PUBMED: 18386204] ">Vaughan 2008</a>). The revision of the fourth edition of the D<i>iagnostic and Statistical Manual of Mental Disorders</i> (<i>DSM‐IV‐TR</i>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1709081242197650432264785567132%26format=REVMAN#REF-APA-2000" target="_blank">APA 2000</a>) defines the most widely used criteria and includes three ADHD subtypes: (1) predominantly inattentive, (2) predominantly hyperactive/impulsive and (3) combined. In 2013, the fifth edition of the DSM (<i>DSM‐5</i>; <a href="./references#CD009504-bbs2-0010" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐5®), Fifth Edition. Arlington (VA): American Psychiatric Publishing, 2013. ">APA 2013</a>) was implemented, resulting in some changes in the diagnostic criteria for ADHD. For example, using <i>DSM‐5</i> , several of the individual’s ADHD symptoms must be present prior to age 12 years, compared to seven years as the age of onset in the<i>DSM‐IV</i> . Also, in the <i>DSM‐5</i> several symptoms need to be present in more than one setting rather than just some impairment in more than one setting. Finally, only five symptoms are needed instead of the six required for younger children, lowering the threshold of symptoms for a reliable diagnosis (<a href="./references#CD009504-bbs2-0010" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐5®), Fifth Edition. Arlington (VA): American Psychiatric Publishing, 2013. ">APA 2013</a>; <a href="./references#CD009504-bbs2-0025" title="Centers for Disease Control and Prevention (CDC). Attention Deficit/Hyperactivity Disorder (ADHD). Symptoms and diagnosis. www.cdc.gov/ncbddd/adhd/diagnosis.html (accessed 19 May 2015). ">CDC 2015</a>). </p> <p>Evidence from genetic, neuroimaging and neuropsychological studies suggest that a number of biological and environmental factors (<a href="./references#CD009504-bbs2-0020" title="BiedermanJ , FaraoneSV . Attention‐deficit hyperactivity disorder. Lancet2005;366(9481):237‐48. [DOI: 10.1016/S0140‐6736(05)66915‐2; PUBMED: 16023516] ">Biederman 2005</a>; <a href="./references#CD009504-bbs2-0032" title="DopheideJA , PliszkaSR . Attention‐deficit‐hyperactivity disorder: an update. Pharmacotherapy2009;29(6):656‐79. [DOI: 10.1592/phco.29.6.656; PUBMED: 19476419] ">Dopheide 2009</a>; <a href="./references#CD009504-bbs2-0102" title="VoellerKK . Attention‐deficit hyperactivity disorder (ADHD). Journal of Child Neurology2004;19(10):798‐814. [DOI: 10.1177/08830738040190100901; PUBMED: 15559895] ">Voeller 2004</a>), each of small individual effect, interact to produce the condition, which is characterised by cognitive and behavioural deficits (<a href="./references#CD009504-bbs2-0094" title="Sonuga‐BarkeEJ . Causal models of attention‐deficit/hyperactivity disorder: from common simple deficits to multiple developmental pathways. Biological Psychiatry2005;57(11):1231‐8. [DOI: 10.1016/j.biopsych.2004.09.008; PUBMED: 15949993] ">Sonuga‐Barke 2005</a>). Putative environmental risk factors related to ADHD can be categorised as biological factors (e.g. fetal exposure to toxins or smoking) or adverse psychosocial factors (e.g. low socioeconomic status, marital discord), but it is unclear which mechanisms underlie these relations (<a href="./references#CD009504-bbs2-0015" title="BanerjeeTD , MiddletonF , FaraoneSV . Environmental risk factors for attention‐deficit hyperactivity disorder. Acta Paediatrica2007;96(9):1269‐74. [DOI: 10.1111/j.1651‐2227.2007.00430.x; PUBMED: 17718779] ">Banerjee 2007</a>). </p> <p>Neurobiological studies highlight that dysregulation of largely dopaminergic (<a href="./references#CD009504-bbs2-0107" title="WangM , VijayraghavanS , Goldman‐RakicPS . Selective D2 receptor actions on the functional circuitry of working memory. Science2004;303(5659):853‐6. [DOI: 10.1126/science.1091162; PUBMED: 14764884] ">Wang 2004</a>) and noradrenergic systems of the frontostriatal circuit appear operant in ADHD (<a href="./references#CD009504-bbs2-0014" title="AshtonH , GallagherP , MooreB . The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorder. Journal of Psychopharmacology2006;20(5):602‐10. [DOI: 10.1177/0269881106061710; PUBMED: 16478756] ">Ashton 2006</a>; <a href="./references#CD009504-bbs2-0023" title="BushG , ValeraEM , SeidmanLJ . Functional neuroimaging of attention‐deficit/hyperactivity disorder: a review and suggested future directions. Biological Psychiatry2005;57(11):1273‐84. [DOI: 10.1016/j.biopsych.2005.01.034; PUBMED: 15949999] ">Bush 2005</a>; <a href="./references#CD009504-bbs2-0114" title="WilensTE . Mechanism of action of agents used in attention‐deficit/hyperactivity disorder. Journal of Clinical Psychiatry2006;67(Suppl 8):32‐8. [PUBMED: 16961428] ">Wilens 2006</a>), leading to its key manifestations. However, even a dopamine/noradrenaline hypothesis of ADHD may be oversimplified, since we may merely be observing the correlates of a process and not the cause. At a clinical, genetic, neuroanatomical and neuropsychological level, marked disparities have been found between subgroups, indicating that ADHD is best conceptualised as a heterogeneous disorder with a complex aetiology (<a href="./references#CD009504-bbs2-0081" title="NuttDJ , FoneK , AshersonP , BrambleD , HillP , MatthewsK , et al. British Association for Psychopharmacology. Evidence‐based guidelines for management of attention‐deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology2007;21(1):10‐41. [DOI: 10.1177/0269881106073219; PUBMED: 17092962] ">Nutt 2007</a>; <a href="./references#CD009504-bbs2-0097" title="SteinhausenHC . The heterogeneity of causes and courses of attention‐deficit/hyperactivity disorder. Acta Psychiatrica Scandinavica2009;120(5):392‐9. [DOI: 10.1111/j.1600‐0447.2009.01446.x; PUBMED: 19807721] ">Steinhausen 2009</a>). </p> <p>Despite the rapidly expanding body of preclinical research on the neurobiological underpinnings of ADHD, the exact aetiological processes are complex and not fully understood. As with most psychiatric disorders, there is no single test that can diagnose ADHD in adulthood. It therefore remains a clinical diagnosis, based on a comprehensive, multifaceted assessment of history and current symptoms and impairments using clinical examination, rating scales, screening instruments, semi‐structured diagnostic interviews and other tools, as indicated (<a href="./references#CD009504-bbs2-0062" title="KooijSJ , BejerotS , BlackwellA , CaciH , Casas‐BruguéM , CarpentierPJ , et al. European consensus statement on diagnosis and treatment of adult ADHD: the European Network Adult ADHD. BMC Psychiatry2010;10:67. [DOI: 10.1186/1471‐244X‐10‐67] ">Kooij 2010</a>). </p> </section> <section id="CD009504-sec-0032"> <h3 class="title" id="CD009504-sec-0032">Description of the intervention</h3> <p>Most of the effective pharmacological treatments for ADHD facilitate catecholamine transmission, either as agonists or as reuptake inhibitors (<a href="./references#CD009504-bbs2-0018" title="BerridgeCW , DevilbissDM , AndrzejewskiME , ArnstenAF , KelleyAE , SchmeichelB , et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biological Psychiatry2006;60(10):1111‐20. [DOI: 10.1016/j.biopsych.2006.04.022; PUBMED: 16806100] ">Berridge 2006</a>; <a href="./references#CD009504-bbs2-0036" title="FaraoneSV , BiedermanJ . Neurobiology of attention‐deficit hyperactivity disorder. Biological Psychiatry1998;44(10):951‐8. [PUBMED: 9821559] ">Faraone 1998</a>; <a href="./references#CD009504-bbs2-0038" title="FaraoneSV , BiedermanJ , SpencerTJ , AleardiM . Comparing the efficacy of medications for ADHD using meta‐analysis. Medscape General Medicine2006;8(4):4. [PUBMED: 17415287] ">Faraone 2006</a>; <a href="./references#CD009504-bbs2-0081" title="NuttDJ , FoneK , AshersonP , BrambleD , HillP , MatthewsK , et al. British Association for Psychopharmacology. Evidence‐based guidelines for management of attention‐deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology2007;21(1):10‐41. [DOI: 10.1177/0269881106073219; PUBMED: 17092962] ">Nutt 2007</a>; <a href="./references#CD009504-bbs2-0111" title="WenderPH , WolfLE , WassersteinJ . Adults with ADHD. An overview. Annals of the New York Academy of Sciences2001;931:1‐16. [PUBMED: 11462736] ">Wender 2001</a>; <a href="./references#CD009504-bbs2-0116" title="YoungJL . Treatment of adult ADHD and comorbid disorders. CNS Spectrums2006;11(S11):10‐2. [DOI: 10.1017/S1092852900025773] ">Young 2006</a>). They can be divided into psychostimulants and nonstimulants. </p> <section id="CD009504-sec-0033"> <h4 class="title">Psychostimulants</h4> <p>Despite the fact that psychostimulant medications are the mainstay of treatment, with a solid track record of safety and efficacy (<a href="./references#CD009504-bbs2-0037" title="FaraoneSV , SpencerT , AleardiM , PaganoC , BiedermanJ . Meta‐analysis of the efficacy of methylphenidate for treating adult attention‐deficit/hyperactivity disorder. Journal of Clinical Psychopharmacology2004;24(1):24‐9. [DOI: 10.1097/01.jcp.0000108984.11879.95; PUBMED: 14709943] ">Faraone 2004</a>; <a href="./references#CD009504-bbs2-0096" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double‐blind, randomized clinical trial of methylphenidate in the treatment of adults with attention‐deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456‐63. [DOI: 10.1016/j.biopsych.2004.11.043; PUBMED: 15737659] ">Spencer 2005</a>), they are either not effective, or tolerated, in approximately 30% to 50% of all adults with ADHD (<a href="./references#CD009504-bbs2-0021" title="BiedermanJ . Introduction: new developments in the treatment of attention‐deficit/hyperactivity disorder. Journal of Clinical Psychiatry2006;67(Suppl 8):4‐6. [PUBMED: 16961423] ">Biederman 2006</a>). Acute dose‐related psychiatric side effects include nervousness, insomnia, psychosis and agitation; somatic side effects include anorexia, weight loss, nausea, headaches and elevated blood pressure and heart rate (<a href="https://archie.cochrane.org/sections/documents/view?version=z1709081242197650432264785567132%26format=REVMAN#REF-Ashton-2006" target="_blank">Ashton 2006</a>). Their reinforcing or euphorigenic effects mean there is a potential for abuse and diversion (<a href="./references#CD009504-bbs2-0065" title="LeonardBE , McCartanD , WhiteJ , KingDJ . Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Human Psychopharmacology2004;19(3):151‐80. [DOI: 10.1002/hup.579; PUBMED: 15079851] ">Leonard 2004</a>; <a href="./references#CD009504-bbs2-0099" title="SwansonJM , VolkowND . Serum and brain concentrations of methylphenidate: implications for use and abuse. Neuroscience and Biobehavioral Reviews2003;27(7):615‐21. [PUBMED: 14624806] ">Swanson 2003</a>; <a href="./references#CD009504-bbs2-0103" title="VolkowND , DingY , FowlerJS , WangGJ , LoganJ , GatleyJS , et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Archives of General Psychiatry1995;52(6):456‐63. [PUBMED: 7771915] ">Volkow 1995</a>; <a href="./references#CD009504-bbs2-0106" title="VolkowND , SwansonJM . Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. American Journal of Psychiatry2003;160(11):1990‐18. [DOI: 10.1176/appi.ajp.160.11.1909; PUBMED: 14594733] ">Volkow 2003</a>; <a href="./references#CD009504-bbs2-0115" title="WolraichML , DoffingMA . Pharmacokinetic considerations in the treatment of attention‐deficit hyperactivity disorder with methylphenidate. CNS Drugs2004;18(4):243‐50. [PUBMED: 15015904] ">Wolraich 2004</a>). A recent Cochrane Review on the beneficial or harmful effects of methylphenidate for the treatment of ADHD in children and adolescents concluded that the magnitude of effect is uncertain, with some evidence that methylphenidate increases the risk of non‐serious adverse events, such as disturbed sleep and reduced appetite, and no evidence that it increases the risk of serious adverse events (<a href="./references#CD009504-bbs2-0098" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>). </p> <p>Psychostimulants are contraindicated in patients who use monoamine oxidase (MAO) inhibitors, who have a history of illicit drug use or abuse, or who suffer from "glaucoma, symptomatic cardiovascular diseases, hyperthyroidism and hypertension" (<a href="./references#CD009504-bbs2-0047" title="GreenhillLL , PliszkaS , DulcanMK , BernetW , ArnoldV , BeitchmanJ , et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. Journal of the American Academy of Child and Adolescent Psychiatry2002;41(2 Suppl):26S‐49S. [PUBMED: 11833633] ">Greenhill 2002</a>). In addition to various medical contraindications, such as untreated bipolar illness, psychosis, anorexia, anxiety disorders and severe depression, the presence of one or more comorbid psychiatric conditions may represent a relative contraindication to using stimulants (<a href="./references#CD009504-bbs2-0077" title="NewcornJH . Nonstimulants and emerging treatments in adults with ADHD. CNS Spectrums2008;13(S13):12‐6. [DOI: 10.1017/S1092852900026857] ">Newcorn 2008a</a>). Although children with ADHD demonstrate a higher rate of emotional dysregulation, which may be exacerbated through the use of stimulants, this has not been systematically demonstrated in adults (<a href="./references#CD009504-bbs2-0041" title="FindlingRL , BramsM , ChildressAC , LópezFA , ManosMJ , JensenPS . Changes in emotions related to medication used to treat ADHD. Part II: clinical approaches. Journal of Attention Disorders2010;15(2):113‐21. [DOI: 10.1177/1087054710381232; PUBMED: 20858786] ">Findling 2010</a>; <a href="./references#CD009504-bbs2-0090" title="SarampoteCS , EfronLA , RobbAS , PearlPL , SteinMA . Can stimulant rebound mimic pediatric bipolar disorder?. Journal of Child and Adolescent Psychopharmacology2004;12(1):63‐7. [DOI: 10.1089/10445460252943588; PUBMED: 12014597] ">Sarampote 2004</a>). Finally, some patients simply will not accept treatment with a psychostimulant (<a href="./references#CD009504-bbs2-0058" title="HimpelS , BanaschewskiT , HeiseCA , RothenbergerA . The safety of non‐stimulant agents for the treatment of attention‐deficit hyperactivity disorder. Expert Opinion on Drug Safety2005;4(2):311‐21. [PUBMED: 15794722] ">Himpel 2005</a>). </p> </section> <section id="CD009504-sec-0034"> <h4 class="title">Nonstimulants</h4> <p>As stimulant medications are not effective or are poorly tolerated in a subset of patients with ADHD, efforts have been made to to expand the current pharmacopoeia to alternative approaches for ADHD (<a href="./references#CD009504-bbs2-0085" title="PliszkaSR . Non‐stimulant treatment of attention‐deficit/hyperactivity disorder. CNS Spectrums2003;8(4):253‐8. [PUBMED: 12679740] ">Pliszka 2003</a>). The majority of nonstimulant compounds target noradrenaline, although there may also be primary and secondary effects on dopamine and other neurotransmitters and neuromodulators (<a href="./references#CD009504-bbs2-0077" title="NewcornJH . Nonstimulants and emerging treatments in adults with ADHD. CNS Spectrums2008;13(S13):12‐6. [DOI: 10.1017/S1092852900026857] ">Newcorn 2008a</a>). In addition to these catecholaminergic agents, the nonstimulants also harbour a variety of investigational drugs that have an effect on various other neurotransmitter systems, including cholinomimetics, histaminergic agonists, modafinil and ampakines, the latter affecting the glutamatergic system. Dopamine and adrenaline reuptake inhibitors (DARI) constitute the focus of this review, amongst which bupropion is the only agent that is clinically available. Bupropion is registered as an antidepressant and it is used as an aid to stop smoking. Given its impact on the catecholaminergic system, bupropion has been used off‐label to treat ADHD (<a href="https://archie.cochrane.org/sections/documents/view?version=z1709081242197650432264785567132%26format=REVMAN#REF-Wilens-2005" target="_blank">Wilens 2005</a>). Two studies have reported a therapeutic effect after several weeks (<a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>), with the largest improvement occurring up to the six‐week endpoint, suggesting a delayed onset of action in adults with ADHD. <a href="https://archie.cochrane.org/sections/documents/view?version=z1709081242197650432264785567132%26format=REVMAN#REF-Reimherr-2005" target="_blank">Reimherr 2005</a> also recommends a six‐week duration for "short‐term, double‐blind studies with bupropion". </p> <p>Although nonstimulants like bupropion, structurally related to amphetamines, are claimed to have a lower potential for abuse, and therefore may be considered for people at risk for substance use, misuse or diversion of stimulants, several cases of recreational use via nasal insufflation and intravenous administration have been reported. In contrast to extensive first‐pass metabolism (FPM) after oral use, nasal insufflation and intravenous use bypass the FPM, resulting in more rapid, higher plasma concentrations (<a href="./references#CD009504-bbs2-0016" title="BaribeauD , ArakiKF . Intravenous bupropion: a previously undocumented method of abuse of a commonly prescribed antidepressant agent. Journal of Addiction Medicine2013;7(3):216‐7. [DOI: 10.1097/ADM.0b013e3182824863; PUBMED: 23519045] ">Baribeau 2013</a>; <a href="./references#CD009504-bbs2-0057" title="HilliardWT , BarloonL , FarleyP , PennJV , KoranekA . Bupropion diversion and misuse in the correctional facility. Journal of Correctional Health Care2013;19(3):211‐7. [DOI: 10.1177/1078345813486448; PUBMED: 23788587] ">Hilliard 2013</a>; <a href="./references#CD009504-bbs2-0082" title="OppekK , KollerG , ZwergalA , PogarellO . Intravenous administration and abuse of bupropion: a case report and a review of the literature. Journal of Addiction Medicine2014;8(4):290‐3. [DOI: 10.1097/ADM.0000000000000044; PUBMED: 24950138] ">Oppek 2014</a>). </p> <p>Pharmacological treatment for ADHD should be provided as part of a multimodal treatment plan, as recommended in international guidelines (<a href="./references#CD009504-bbs2-0022" title="Bolea‐AlamañacB , NuttDJ , AdamouM , AshersonP , BazireS , CoghillD , et al. Evidence‐based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology2014;28(3):179‐203. [DOI: 10.1177/0269881113519509; PUBMED: 24526134] ">Bolea‐Alamañac 2014</a>; <a href="./references#CD009504-bbs2-0024" title="Canadian Attention Deficit Hyperactivity Disorder Resource Alliance(CADDRA) . Canadian ADHD Practice Guidelines (CAP‐Guidlines), 3rd Edition. www.caddra.ca/practice‐guidelines (accessed prior to 30 May 2017). ">CADDRA 2011</a>; <a href="./references#CD009504-bbs2-0079" title="National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults (NICE guidelines CG72). www.nice.org.uk/guidance/cg72 (accessed 19 May 2015). ">NICE 2008</a>). As opposed to ADHD treatment guidelines in children, current UK guidelines recommend adults with ADHD be given pharmacological interventions as first‐line therapy, unless psychological treatments are preferred (<a href="./references#CD009504-bbs2-0079" title="National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults (NICE guidelines CG72). www.nice.org.uk/guidance/cg72 (accessed 19 May 2015). ">NICE 2008</a>). This recommendation is, in part, based on a paucity of evidence for the efficacy of using non‐drug interventions alone (<a href="./references#CD009504-bbs2-0022" title="Bolea‐AlamañacB , NuttDJ , AdamouM , AshersonP , BazireS , CoghillD , et al. Evidence‐based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology2014;28(3):179‐203. [DOI: 10.1177/0269881113519509; PUBMED: 24526134] ">Bolea‐Alamañac 2014</a>). </p> <p>Several systematic reviews have evaluated the effects of different types of medication for adult ADHD. <a href="./references#CD009504-bbs2-0083" title="PetersonK , McDonaghMS , FuR . Comparative benefits and harms of competing medications for adults with attention‐deficit hyperactivity disorder: a systematic review and indirect comparison meta‐analysis. Psychopharmacology2008;197(1):1‐11. [DOI: 10.1007/s00213‐007‐0996‐4; PUBMED: 18026719] ">Peterson 2008</a> compared the benefits and harms of short‐acting stimulants, long‐acting stimulants and nonstimulants (three studies of bupropion) using an indirect comparison meta‐analysis. The relative effects of short‐acting stimulants were superior to those of bupropion (risk ratio (RR) 2.24, 95% confidence interval (CI) 1.23 to 4.08) and of long‐acting stimulants (RR 3.26, 95% CI 2.03 to 5.22). <a href="./references#CD009504-bbs2-0039" title="FaraoneSV , GlattSJ . A comparison of the efficacy of medications for adult attention‐deficit/hyperactivity disorder using meta‐analysis of effect sizes. Journal of Clinical Psychiatry2010;71(6):754‐63. [DOI: 10.4088/JCP.08m04902pur; PUBMED: 20051220] ">Faraone 2010</a> estimated effect sizes of medications and found that both stimulants and nonstimulants appeared to be effective. Stimulants showed larger effects, as illustrated by the number needed to treat for an additional beneficial outcome (NNTB). For bupropion, the NNTB approached five, while for stimulants the NNTB was nearer two. <a href="./references#CD009504-bbs2-0069" title="ManeetonN , ManeetonB , IntaprasertS , WoottilukP . A systematic review of randomized controlled trials of bupropion versus methylphenidate in the treatment of attention‐deficit/hyperactivity disorder. Neuropsychiatric Disease and Treatment2014;10:1439‐49. [DOI: 10.2147/NDT.S62714; PMC4128852; PUBMED: 25120365] ">Maneeton 2014</a> compared bupropion versus methylphenidate. Based on four small studies, they found no difference in effects and tolerability between the two drugs. <a href="./references#CD009504-bbs2-0075" title="MoriyamaTS , PolanczykGV , TerziFS , FariaKM , RohdeLA . Psychopharmacology and psychotherapy for the treatment of adults with ADHD—a systematic review of available meta‐analyses. CNS Spectrums2013;18(6):296‐306. [DOI: 10.1017/S109285291300031X; PUBMED: 23739183] ">Moriyama 2013</a> systematically reviewed meta‐analyses on pharmacological interventions for adults with ADHD, including the <a href="./references#CD009504-bbs2-0039" title="FaraoneSV , GlattSJ . A comparison of the efficacy of medications for adult attention‐deficit/hyperactivity disorder using meta‐analysis of effect sizes. Journal of Clinical Psychiatry2010;71(6):754‐63. [DOI: 10.4088/JCP.08m04902pur; PUBMED: 20051220] ">Faraone 2010</a> and <a href="./references#CD009504-bbs2-0083" title="PetersonK , McDonaghMS , FuR . Comparative benefits and harms of competing medications for adults with attention‐deficit hyperactivity disorder: a systematic review and indirect comparison meta‐analysis. Psychopharmacology2008;197(1):1‐11. [DOI: 10.1007/s00213‐007‐0996‐4; PUBMED: 18026719] ">Peterson 2008</a> reviews. The review authors concluded that bupropion was inferior to stimulants. Two previous reviews compared bupropion to placebo: <a href="./references#CD009504-bbs2-0039" title="FaraoneSV , GlattSJ . A comparison of the efficacy of medications for adult attention‐deficit/hyperactivity disorder using meta‐analysis of effect sizes. Journal of Clinical Psychiatry2010;71(6):754‐63. [DOI: 10.4088/JCP.08m04902pur; PUBMED: 20051220] ">Faraone 2010</a> compared effect sizes while <a href="./references#CD009504-bbs2-0068" title="ManeetonN , ManeetonB , SrisurapanontM , MartinSD . Bupropion for adults with attention‐deficit hyperactivity disorder: meta‐analysis of randomized, placebo‐controlled trials. Psychiatry and Clinical Neurosciences2011;65(7):611‐7. [DOI: 10.1111/j.1440‐1819.2011.02264.x; PUBMED: 22176279] ">Maneeton 2011</a> compared both effects and safety. Both concluded that bupropion was superior to placebo. </p> </section> </section> <section id="CD009504-sec-0035"> <h3 class="title" id="CD009504-sec-0035">How the intervention might work</h3> <p>Bupropion is an aminoketone antidepressant and non‐competitive antagonism of nicotinic acetylcholine receptors (<a href="./references#CD009504-bbs2-0043" title="GobbiG , SlaterS , BoucherN , DebonnelG , BlierP . Neurochemical and psychotropic effects of bupropion in healthy male subjects. Journal of Clinical Psychopharmacology2003;23(3):233‐9. [DOI: 10.1097/01.jcp.0000084023.22282.03; PUBMED: 12826985] ">Gobbi 2003</a>). Its mechanism of action most likely involves reuptake inhibition of the catecholamines, dopamine and noradrenaline, a profile similar to the presumed action of psychostimulants. The powerful influence that catecholamines have on brain circuits, which appear to be altered in ADHD, are mediated through stimulation of dopamine 1 (D1) and noradrenergic 2a receptors, respectively (<a href="./references#CD009504-bbs2-0012" title="ArnstenAF , LiBM . Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biological Psychiatry2005;57(11):1377‐84. [DOI: 10.1016/j.biopsych.2004.08.019; PUBMED: 15950011] ">Arnsten 2005</a>). A study published almost 30 years ago on the biochemical effects of bupropion in depressed people concluded that the rise in plasma homovanillic acid (HVA) level in bupropion nonresponders may represent a perturbation of dopaminergic systems (<a href="./references#CD009504-bbs2-0044" title="GoldenRN , RudorferMV , ShererMA , LinnoilaM , PotterWZ . Bupropion in depression. I Biochemical effects and clinical response. Archives of General Psychiatry1988;45(2):139‐43. [PUBMED: 3122698] ">Golden 1988a</a>). Whole‐body noradrenaline turn‐over in depressed people was reduced without altering plasma levels of noradrenaline at rest and following an orthostatic challenge. The effect of bupropion on cerebrospinal fluid (CSF) monoamine metabolite concentrations lacked significance, but may have been due to an alpha error (<a href="./references#CD009504-bbs2-0044" title="GoldenRN , RudorferMV , ShererMA , LinnoilaM , PotterWZ . Bupropion in depression. I Biochemical effects and clinical response. Archives of General Psychiatry1988;45(2):139‐43. [PUBMED: 3122698] ">Golden 1988a</a>). The major metabolites of bupropion have substantially longer half‐lives than the parent compound. The half‐lives of hydroxybupropion (HB), erythrohydrobupropion and threohydrobupropion were 27, 43 and 50 hours, respectively. Thus, the longer half‐lives of these active metabolites should be taken into consideration when calculating when steady state has been reached in people receiving bupropion (<a href="./references#CD009504-bbs2-0045" title="GoldenRN , DeVaneCL , LaizureSC , RudorferMV , ShererMA , PotterWZ . Bupropion in depression. II. The role of metabolites in clinical outcome. Archives of General Psychiatry1988;45(2):145‐9. [PUBMED: 3122699] ">Golden 1988b</a>). Higher plasma metabolite concentrations were associated with poor clinical outcome. This relationship was most striking with HB, and may suggest a curvilinear dose‐response relationship, similar to that seen with nortriptyline, for the bupropion metabolites. </p> <p>Studies have demonstrated similar bioavailability for immediate‐, sustained‐ and extended‐release bupropion, but information about their efficacy and the occurrence of adverse effects is scarce. The spontaneous seizure rate reported in the general population is approximately 0.1% (<a href="./references#CD009504-bbs2-0084" title="PisaniF , OteriG , CostaC , DiRaimondoG , DiPerriR . Effects of psychotropic drugs on seizure threshold. Drug Safety2002;25(2):91‐110. [PUBMED: 11888352] ">Pisani 2002</a>), whereby the incidence of a convulsion rises significantly at dosages higher than 450 mg per day, the highest recommended dose (<a href="./references#CD009504-bbs2-0095" title="SpencerT , BiedermanJ , WilensT . Nonstimulant treatment of adult attention‐deficit/hyperactivity disorder. Psychiatric Clinics of North America2004;27(2):373‐83. [DOI: 10.1016/j.psc.2003.12.001; PUBMED: 15064003] ">Spencer 2004</a>). Also, some people taking the drug have developed anxiety, some have developed headaches (<a href="./references#CD009504-bbs2-0089" title="RostainAL . Attention‐deficit/hyperactivity disorder in adults: evidence‐based recommendations for management. Postgraduate Medicine2008;120(3):27‐38. [DOI: 10.3810/pgm.2008.09.1905; PUBMED: 18824823] ">Rostain 2008</a>), and others have reported exacerbation of tic disorders (<a href="./references#CD009504-bbs2-0086" title="PopperCW . Antidepressants in the treatment of ADHD. Journal of Clinical Psychiatry1997;58(Suppl 14):14‐29. [PUBMED: 9418743] ">Popper 1997</a>). The potential increase in blood pressure is usually small and only of concern in those with marginal or high blood pressure. Bupropion shows little impact on weight and sexual function (<a href="./references#CD009504-bbs2-0030" title="DemyttenaereK , JaspersL . Review: bupropion and SSRI‐induced side effects. Journal of Psychopharmacology2008;22(7):792‐804. [DOI: 10.1177/0269881107083798; PUBMED: 18308785] ">Demyttenaere 2008</a>; <a href="./references#CD009504-bbs2-0113" title="WilensTE , DodsonW . A clinical perspective of attention‐deficit/hyperactivity disorder into adulthood. Journal of Clinical Psychiatry2004;65(10):1301‐13. [PUBMED: 15491232] ">Wilens 2004</a>). Dose‐related side effects are mediated via the catecholamines transmitters. The mechanism of idiosyncratic side effects is unknown. </p> <p>Bupropion appears to be effective in adolescents with ADHD and comorbid drug misuse and mood disorders (<a href="./references#CD009504-bbs2-0093" title="SolhkhahR , WilensTE , DalyJ , PrinceJB , VanPattenSL , BiedermanJ . Bupropion SR for the treatment of substance‐abusing outpatient adolescents with attention‐deficit/hyperactivity disorder and mood disorders. Journal of Child and Adolescent Psychopharmacology2005;15(5):777‐86. [DOI: 10.1089/cap.2005.15.777; PUBMED: 16262594] ">Solhkhah 2005</a>). There are few data regarding the most effective formulation and dosing of bupropion. There is also a lack of clarity about whether there is a differential response rate to bupropion according to the patient's ADHD subtype. Depression is often comorbid with ADHD and can influence ADHD symptoms, suggesting that bupropion, which is an antidepressant, may reduce ADHD symptoms only in the presence of depression. Although there is some evidence that bupropion may be useful in treating adolescents with ADHD and comorbid depression (<a href="./references#CD009504-bbs2-0028" title="DavissWB , BentivoglioP , RacusinR , BrownKM , BosticJQ , WileyL . Bupropion sustained release in adolescents with comorbid attention‐deficit/hyperactivity disorder and depression. Journal of the American Academy of Child Adolescent Psychiatry2001;40(3):307‐14. [DOI: 10.1097/00004583‐200103000‐00010; PUBMED: 11288772] ">Daviss 2001</a>), no studies of good quality have addressed the issue in adults. </p> <p>Both bupropion and methylphenidate are dopamine and noradrenaline re‐uptake inhibitors at the presynapse. However, the re‐uptake inhibition is less strong for bupropion, as reflected by the half maximal inhibitory concentration (IC₅₀), which is a measure of the effectiveness of a compound. </p> <p>Four positron emission tomography (PET) studies have been conducted in healthy and depressed individuals to gain information about the contribution of dopamine transporter (DAT‐) inhibition to the pharmacological mechanism of action of bupropion (<a href="./references#CD009504-bbs2-0011" title="ArgyelánM , SzabóZ , KanyóB , TanácsA , KovácsZ , JankaZ , et al. Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc‐TRODAT‐1 SPECT study. Journal of Affective Disorders2005;89(1‐3):115‐23. [DOI: 10.1016/j.jad.2005.08.016; PUBMED: 16213028] ">Argyelán 2005</a>; <a href="./references#CD009504-bbs2-0034" title="EgertonA , ShotboltJP , StokesPR , HiraniE , AhmadR , LappinJM , et al. Acute effect of the anti‐addiction drug bupropion on extracellular dopamine concentrations in the human striatum: an [11C]raclopride PET study. Neuroimage2010;50(1):260‐6. [DOI: 10.1016/j.neuroimage.2009.11.077; PMC4135078; PUBMED: 19969097] ">Egerton 2010</a>; <a href="./references#CD009504-bbs2-0064" title="Learned‐CoughlinSM , BergströmM , SavitchevaI , AscherJ , SchmithVD , LångstromB . In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biological Psychiatry2003;54(8):800‐5. [PUBMED: 14550679] ">Learned‐Coughlin 2003</a>; <a href="./references#CD009504-bbs2-0073" title="MeyerJH , GouldingVS , WilsonAA , HusseyD , ChristensenBK , HouleS . Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology2002;163(1):102‐5. [DOI: 10.1007/s00213‐002‐1166‐3; PUBMED: 12185406] ">Meyer 2002</a>). All of these studies showed a DAT occupancy of approximately 20% during exposure to bupropion (and its metabolites). This raises the question of whether these low DAT‐occupancy rates are therapeutic or whether bupropion derives its efficacy from another mechanism. In contrast, weight‐adjusted doses of methylphenidate used therapeutically are likely to occupy more than 50% of the dopamine transporters (<a href="./references#CD009504-bbs2-0104" title="VolkowND , WangGJ , FowlerJS , GatleySJ , LoganJ , DingYS , et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. American Journal of Psychiatry1998;155(10):1325‐31. [DOI: 10.1176/ajp.155.10.1325; PUBMED: 9766762] ">Volkow 1998</a>; <a href="./references#CD009504-bbs2-0105" title="VolkowND , WangGJ , FowlerJS , LoganJ , FranceschiD , MaynardL , et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse2002;143(3):181‐7. [DOI: 10.1002/syn.10038; PUBMED: 11793423] ">Volkow 2002</a>). </p> <p>The tolerability profile of bupropion is well documented, with thousands of participants in clinical trials and over 40 million clinical‐use exposures for all uses. The most common adverse effects (incidence higher than 10%) found to be associated with the use of bupropion are headache (27% for bupropion versus 23% for placebo), dry mouth (16% for bupropion versus 7% for placebo; P &lt; 0.05), nausea (13% for bupropion versus 8% for placebo; P &lt; 0.05), and insomnia (11% for bupropion versus 7% for placebo; P &lt; 0.05) (<a href="./references#CD009504-bbs2-0061" title="JeffersonJW , PradkoJF , MuirKT . Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clinical Therapeutics2005;27(11):1685‐95. [DOI: 10.1016/j.clinthera.2005.11.011; PUBMED: 16368442] ">Jefferson 2005</a>). In addition, there is an elevated risk of drug‐induced seizures with bupropion (0.1% at doses up to 300 mg a day with a sustained‐release formulation and 0.4% at doses up to 450 mg a day with an immediate‐release formulation). To minimise the risk for seizure, patients should be screened for predisposing factors, clinical situations, and concomitant medications that may decrease seizure threshold (<a href="./references#CD009504-bbs2-0061" title="JeffersonJW , PradkoJF , MuirKT . Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clinical Therapeutics2005;27(11):1685‐95. [DOI: 10.1016/j.clinthera.2005.11.011; PUBMED: 16368442] ">Jefferson 2005</a>). </p> <p>Bupropion hydrochloride, a noradrenergic/dopaminergic antidepressant, is available as immediate‐release (given three times a day), sustained‐release (given twice a day), and extended‐release (given once a day) oral formulations. The mean elimination half‐life of bupropion is 21 hours, which is similar to that of hydroxy‐bupropion (20 hours). The elimination half‐life values of erythrohydrobupropion and threohydrobupropion are longer (33 and 37 hours, respectively). Seven to 10 days are therefore required for bupropion and its metabolites to reach steady state. Sustained‐release and extended‐release bupropion have been found to be bioequivalent to the immediate‐release formulation and to each other. Bioequivalence criteria included demonstration of equivalent delivery of the drug via the respective formulations when multiple doses were administered until steady state was achieved. Patients being converted from one formulation to another should be given the same daily dose that they are currently receiving (<a href="./references#CD009504-bbs2-0031" title="DhillonS , YangLP , CurranMP . Bupropion: a review of its use in the management of major depressive disorder. Drugs2008;68(5):653‐89. [PUBMED: 18370448] ">Dhillon 2008</a>). </p> </section> <section id="CD009504-sec-0036"> <h3 class="title" id="CD009504-sec-0036">Why it is important to do this review</h3> <p>The high ADHD prevalence rate, incomplete response and/or adverse drug reactions to stimulants, as well as the risk of stimulant abuse mean that pharmacotherapeutic alternatives to stimulants, such as bupropion, should be explored. </p> <p>Although buproprion is widely used as a treatment for ADHD, data from randomised controlled trials regarding its effectiveness are lacking (<a href="https://archie.cochrane.org/sections/documents/view?version=z1709081242197650432264785567132%26format=REVMAN#REF-Reimherr-2005" target="_blank">Reimherr 2005</a>). It is of both clinical and research interest to document the efficacy of buproprion for ADHD, as it might generate new avenues of research that inform us of the aetiology of ADHD (<a href="https://archie.cochrane.org/sections/documents/view?version=z1709081242197650432264785567132%26format=REVMAN#REF-Reimherr-2005" target="_blank">Reimherr 2005</a>). It is likely that there is a differential response to stimulant and nonstimulant drugs in adults with ADHD. Patients may prefer one treatment to the other (<a href="./references#CD009504-bbs2-0078" title="NewcornJH , KratochvilCJ , AllenAJ , CasatCD , RuffDD , MooreRJ , et al. Atomoxetine/Methylphenidate Comparative Study Group. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. American Journal of Psychiatry2008;165(6):721‐30. [DOI: 10.1176/appi.ajp.2007.05091676; PUBMED: 18281409] ">Newcorn 2008b</a>). A major challenge for the future is to develop strategies to identify a priori those people who will prefer a stimulant over a nonstimulant drug. At present, there are a lack of empirical data to guide such treatment selection. </p> <p>A nonscheduled agent such as bupropion does not produce euphoria and so may be used in patients who have a history of illicit drug use and abuse (<a href="https://archie.cochrane.org/sections/documents/view?version=z1709081242197650432264785567132%26format=REVMAN#REF-Young-2006" target="_blank">Young 2006</a>). Differing patterns of comorbidity and symptom heterogeneity pose different treatment challenges. As psychostimulants are relatively contraindicated in people with ADHD and comorbid conditions, such as depression, anxiety and substance misuse, it is vital to explore nonstimulant treatment options. </p> <p>When proper symptom control and functional improvement cannot be met by licensed medicines, clinicians resort to off‐label use (<a href="./references#CD009504-bbs2-0081" title="NuttDJ , FoneK , AshersonP , BrambleD , HillP , MatthewsK , et al. British Association for Psychopharmacology. Evidence‐based guidelines for management of attention‐deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology2007;21(1):10‐41. [DOI: 10.1177/0269881106073219; PUBMED: 17092962] ">Nutt 2007</a>). This is the case with bupropion for adults with ADHD. It is important that the effectiveness and safety of such off‐label use of bupropion is assessed, which is the purpose of this review. A systematic review may reduce the uncertainty that remains about recommended optimum prescribing hierarchies that vary between different guideline committees. Our review updates two previously published systematic reviews on bupropion (<a href="./references#CD009504-bbs2-0039" title="FaraoneSV , GlattSJ . A comparison of the efficacy of medications for adult attention‐deficit/hyperactivity disorder using meta‐analysis of effect sizes. Journal of Clinical Psychiatry2010;71(6):754‐63. [DOI: 10.4088/JCP.08m04902pur; PUBMED: 20051220] ">Faraone 2010</a>; <a href="./references#CD009504-bbs2-0068" title="ManeetonN , ManeetonB , SrisurapanontM , MartinSD . Bupropion for adults with attention‐deficit hyperactivity disorder: meta‐analysis of randomized, placebo‐controlled trials. Psychiatry and Clinical Neurosciences2011;65(7):611‐7. [DOI: 10.1111/j.1440‐1819.2011.02264.x; PUBMED: 22176279] ">Maneeton 2011</a>), while using the latest rigorous systematic review methodology to come to a trustworthy answer to our clinical question. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009504-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009504-sec-0037"></div> <p>To assess the effects and safety of bupropion for the treatment of adults with ADHD.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009504-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009504-sec-0038"></div> <section id="CD009504-sec-0039"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009504-sec-0040"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs), including acute studies (less than 24 hours), as well as short‐term (less than six weeks), medium‐term (six weeks to six months), and long‐term studies (more than six months). </p> </section> <section id="CD009504-sec-0041"> <h4 class="title">Types of participants</h4> <p>Adults aged 18 years or older, diagnosed with ADHD according to formal, standardised diagnostic criteria (<i>Wender Utah criteria</i> (<a href="./references#CD009504-bbs2-0108" title="WardMF , WenderPH , ReimherrFW . The Wender Utah Rating Scale (WURS): an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. American Journal of Psychiatry1993;150(6):885‐90. [DOI: 10.1176/ajp.150.6.885; PUBMED: 8494063] ">Ward 1993</a>); <i>Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision</i> (<i>DSM IV‐TR</i>; <a href="./references#CD009504-bbs2-0009" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington (DC): APA, 2000. ">APA 2000</a>); <i>International Classification of Diseases, 10th Revision</i> (<i>ICD 10;</i><a href="./references#CD009504-bbs2-0112" title="World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD‐10). Vol. 10th revision, WHO, 2010. ">WHO 2011</a>)). We included all ADHD subtypes. We did not exclude comorbid psychiatric conditions. </p> </section> <section id="CD009504-sec-0042"> <h4 class="title">Types of interventions</h4> <p>Any formulation of bupropion (bupropion, extended‐release bupropion, sustained‐release bupropion), at any dose, compared with placebo. We did not exclude studies with adjuvant interventions if they were provided to both arms of the study. </p> </section> <section id="CD009504-sec-0043"> <h4 class="title">Types of outcome measures</h4> <section id="CD009504-sec-0044"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD009504-list-0001"> <li> <p>Efficacy outcomes.</p> <ol id="CD009504-list-0002"> <li> <p>Change in severity of ADHD symptoms from baseline, as assessed by a standardised instrument (participant‐ or investigator‐rated) such as the Wender‐Reimherr Adult Attention Deficit Disorder Scale (WRAADS; <a href="./references#CD009504-bbs2-0070" title="Marchant , BK , ReimherrFW , RobisonD , RobisonRJ , WenderPH . Psychometric properties of the Wender‐Reimherr Adult Attention Deficit Disorder Scale. Psychological AssessmentSept 2013;25(3):942‐50. [DOI: 10.1037/a0032797; PUBMED: 23647041] ">Marchant 2013</a>), ADHD Rating Scale (ADHD‐RS; <a href="./references#CD009504-bbs2-0033" title="DuPaulGJ . The ADHD Rating Scale: Normative Data, Reliability, and Validity. Worchester (MA): University of Massachusetts Medical Center, 1990. ">DuPaul 1990</a>) or the Adult ADHD Rating Scale (AARS; <a href="./references#CD009504-bbs2-0076" title="MurphyK , BarkleyRA . Prevalence of DSM‐IV symptoms of ADHD in adult licensed drivers: implications for clinical diagnosis. Journal of Attention Disorders1996;1(3):147‐61. [DOI: 10.1177/108705479600100303] ">Murphy 1996</a>). </p> </li> <li> <p>Proportion of participants achieving a significant clinical improvement. Significant improvement is defined as a reduction of at least 30% in the severity of ADHD symptoms or a score of one or two on the Clinical Global Impression (CGI)‐Improvement scale (<a href="./references#CD009504-bbs2-0080" title="National Institute of Mental Health. CGI (Clinical Global Impression Scale). Psychopharmacology Bulletin1985;21:839‐44. ">NIMH 1984</a>). </p> </li> </ol> </li> <li> <p>Any adverse effects.</p> <ol id="CD009504-list-0003"> <li> <p>Proportion of participants withdrawn due to any adverse effect (somatic or psychiatric).</p> </li> </ol> </li> </ol> </p> </section> <section id="CD009504-sec-0045"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD009504-list-0004"> <li> <p>Efficacy outcomes.</p> <ol id="CD009504-list-0005"> <li> <p>Clinical impression, as measured by the CGI‐Severity of illness scale (<a href="./references#CD009504-bbs2-0048" title="GuyW . Clinical global impressions. In: US Department of Health, Education , Welfare Public Health Service, Alcohol , Drug Abuse and Mental Health Administration, editor(s). ECDEU Assessment Manual for Psychopharmacology. Rockville (MD): NIMH Psychopharmacology Research Branch, 1976:218‐222. ">Guy 1976</a>). </p> </li> <li> <p>Global level of functioning, as measured by the Global Assessment of Functioning (GAF) scale (<a href="./references#CD009504-bbs2-0046" title="GoldmanHH , SkodolAE , LaveTR . Revising axis V for DSM‐IV: a review of measures of social functioning. American Journal of Psychiatry1992;149(9):1148‐56. [DOI: 10.1176/ajp.149.9.1148; PUBMED: 1386964] ">Goldman 1992</a>). </p> </li> <li> <p>Social adjustment, as measured by a social adjustment scale such as the Social Adjustment Scale ‐ Self‐report (SAS‐SR; <a href="./references#CD009504-bbs2-0110" title="WeissmanMM . Social Adjustment Scale – Self‐report Technical Manual. Toronto (OT): Multi‐Health Systems, 1999. ">Weissman 1999</a>). </p> </li> <li> <p>Depressive symptoms, as assessed by standardised instruments such as the Hamilton Depression Rating Scale (HAM‐D; <a href="./references#CD009504-bbs2-0053" title="HamiltonM . A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry1960;23:56‐62. [10.1136/jnnp.23.1.56 PMID 14399272] ">Hamilton 1960</a>). </p> </li> <li> <p>Anxiety, as assessed by standardised instruments such as the Hamilton Anxiety Rating Scale (HAM‐A; <a href="./references#CD009504-bbs2-0067" title="MaierW , BullerR , PhilippM , HeuserI . The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. Journal of Affective Disorders1988;14(1):61‐8. [PUBMED: 2963053] ">Maier 1988</a>). </p> </li> </ol> </li> <li> <p>Somatic or psychiatric adverse effects.</p> <ol id="CD009504-list-0006"> <li> <p>Proportion of participants withdrawn due to any somatic adverse effect such as headache or nausea. </p> </li> <li> <p>Proportion of participants withdrawn due to any psychiatric adverse effect such as agitation, insomnia or problems with concentration. </p> </li> </ol> </li> </ol> </p> <p>All primary outcomes are included in <a href="./full#CD009504-tbl-0001">summary of findings Table for the main comparison</a>. Although we anticipated classifying outcomes of all studies based on time of measurement from randomisation (see <a href="#CD009504-tbl-0002">Table 1</a>), none of the studies reported outcomes at multiple time points. </p> <div class="table" id="CD009504-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Methods archived for future updates of this review</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Topic</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Method</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unit of analysis issues</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross‐over trials</b> </p> <p>We will include cross‐over trials. Given the risk of carry‐over effects, we will use data from the first period (before cross‐over) only, and treat these as parallel‐group trials. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Assessment of reporting biases</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We will produce funnel plots (estimated treatment effects against their standard error). We will test funnel plot asymmetry when there are at least 10 studies included in the meta‐analysis. Asymmetry could be due to publication bias, but could also be due to a relationship between trial size and effect size. In the event that we find a relationship, we will examine the clinical diversity of the studies, selection biases and poor methodological quality as alternative explanations to publication bias. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Subgroup analysis and investigation of heterogeneity</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We will perform two subgroup analyses:</p> <p> <ol id="CD009504-list-0007"> <li> <p>Type of drug release formulation: immediate release, sustained release and extended release. </p> </li> <li> <p>Dose: above versus below median dose.</p> </li> </ol> </p> <p>When there are more than 10 studies included in the analyses, we will investigate statistical heterogeneity using meta‐regression (<a href="./references#CD009504-bbs2-0029" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Multiple time points</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We will classify outcomes of all studies based on time of measurement from randomisation: acute (less than 24 hours), short‐term (less than six weeks), medium‐term (six weeks to six months), and long‐term (more than six months). Within each time period, we will include the latest outcome in the meta‐analysis. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sensitivity analysis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We will conduct sensitivity analyses to determine whether findings are sensitive to restricting the analyses to studies judged to be at low risk of bias. In these analyses, we will restrict the analysis to the following: </p> <p> <ol id="CD009504-list-0008"> <li> <p>Studies with low risk of selection bias (associated with sequence generation and allocation concealment). </p> </li> <li> <p>Studies without financial support from the pharmaceutical industry.</p> </li> <li> <p>Studies that used standardised instrument(s) to measure efficacy.</p> </li> <li> <p>Studies without imputed data (see also 'Dealing with missing data').</p> </li> </ol> </p> </td> </tr> </tbody> </table> </div> </section> </section> </section> <section id="CD009504-sec-0046"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD009504-sec-0047"> <h4 class="title">Electronic searches</h4> <p>We ran the first searches for this review in January 2012. We updated the searches in September 2014, November 2015 and February 2017. We did not limit the searches by date or language. </p> <p> <ol id="CD009504-list-0009"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 1); in the Cochrane LIbrary, which includes the Cochrane Developmental, Psychosocial and Learning Problems Specialised Register (searched 20 February 2017)<i>.</i> </p> </li> <li> <p>MEDLINE Ovid (1946 to February Week 5 2017).</p> </li> <li> <p>MEDLINE Ovid In‐Process &amp; Other Non‐Indexed Citations (17 February 2017).</p> </li> <li> <p>MEDLINE Ovid Epub Ahead of Print (17 February 2017).</p> </li> <li> <p>Embase Ovid (1980 to 2017 Week 8).</p> </li> <li> <p>PsycINFO Ovid (1806 to November Week 2 2017).</p> </li> <li> <p>Cumulative Index to Nursing and Allied Health Literature (CINAHL Plus EBSCOhost; 1937 to 21 February 2017). </p> </li> <li> <p>Science Citation Index ‐ EXPANDED Web of Science (SCI‐EXPANDED; 1970 to 20 February 2017). </p> </li> <li> <p>Social Sciences Citation Index Web of Science (SSCI; 1970 to 20 February 2017).</p> </li> <li> <p>Conference Proceedings Citation Index ‐ Science Web of Science (CPCI‐S; 1990 to 20 February 2017). </p> </li> <li> <p>Conference Proceedings Citation Index ‐ Social Science &amp; Humanities Web of Science (CPCI‐SS&amp;H; 1990 to 20 February 2017). </p> </li> <li> <p>Latin American and Caribbean Health Science Information (LILACS) database; <a href="http://bases.bireme.br/cgi-bin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis%26base=LILACS%E2%8C%A9=i%26form=A" target="_blank">bases.bireme.br</a>; searched 21 February 2017). </p> </li> <li> <p>WorldCat (limited to theses) (<a href="http://worldcat.org" target="_blank">worldcat.org</a>; searched 21 February 2017). </p> </li> <li> <p>metaRegister of Controlled Trials (<i>m</i>RCT; <a href="http://isrctn.com/page/mrct" target="_blank">isrctn.com/page/mrct</a>; last searched 2 October 2014. Service is currently under review). </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP; <a href="http://apps.who.int/trialsearch/Default.aspx" target="_blank">apps.who.int/trialsearch/Default.aspx</a>; searched 21 February 2017). </p> </li> <li> <p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>; searched 21 February 2017). </p> </li> <li> <p>Netherlands Trials Register (<a href="http://trialregister.nl/trialreg/index.asp" target="_blank">trialregister.nl/trialreg/index.asp</a>; searched 21 February 2017). </p> </li> <li> <p>Networked Digital Library of Theses and Dissertations (<a href="http://ndltd.org/" target="_blank">ndltd.org</a>, searched 21 February 2017). </p> </li> <li> <p>DART ‐ Europe E‐theses Portal (<a href="http://dart-europe.eu/" target="_blank">dart‐europe.eu</a>, searched 21 February 2017). </p> </li> </ol> </p> <p>The search strategies and search dates for each source are reported in <a href="./appendices#CD009504-sec-0122">Appendix 1</a>. </p> </section> <section id="CD009504-sec-0048"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of all relevant reports for further studies. We also contacted colleagues, experts and pharmaceutical companies in the field, to ascertain if there were any ongoing or unpublished studies. </p> </section> </section> <section id="CD009504-sec-0049"> <h3 class="title" id="CD009504-sec-0049">Data collection and analysis</h3> <section id="CD009504-sec-0050"> <h4 class="title">Selection of studies</h4> <p>Two review authors (WV, GB) screened titles and abstracts of all identified studies for relevance. The same two review authors screened the full texts of studies that we deemed potentially relevant or for which we needed more information. We resolved any disagreements by consensus. We reported our study selection process in a PRISMA study flow diagram (<a href="./references#CD009504-bbs2-0074" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Medicine2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097; PMC2707599; PUBMED: 19621072] ">Moher 2009</a>). </p> </section> <section id="CD009504-sec-0051"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (WV, GB), working independently, extracted data using a data extraction sheet that we tested in a pilot study. <a href="./appendices#CD009504-sec-0139">Appendix 2</a> provides an overview of the data that we extracted, resolving any disagreements by consensus. In case of missing information with respect to study quality (all studies) or with respect to study results (<a href="./references#CD009504-bbs2-0001" title="HamediM , MohammadiM , GhaleihaA , KeshavarziZ , JafariniaM , KeramatfarR , et al. Bupropion in adults with attention‐deficit/hyperactivity disorder: a randomized double‐blinded study. Acta Medica Iranica2014;52(9):675‐80. [PUBMED: 25325205] ">Hamedi 2014</a>; <a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>; <a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>), we emailed the respective study authors to request this information. We considered data as 'missing' if the study authors could not provide the information or if they did not respond. </p> </section> <section id="CD009504-sec-0052"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two reviewers (WV and GB) independently assessed the risks of bias of each included study using the Cochrane 'Risk of bias' tool (<a href="./references#CD009504-bbs2-0056" title="HigginsJPT , AltmanDG , SterneJAC , editor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). This tool consists of six domains. For each domain, we judged the risk of bias to be 'low', 'high' or 'unclear', using criteria outlined by the tool. The criteria are explained below. </p> <section id="CD009504-sec-0053"> <h5 class="title">1. Random sequence generation</h5> <p>We rated studies that used adequate methods to generate the random sequence, such as computer‐generated randomisation lists, as being at low risk of bias. We rated studies that used inadequate methods, such as date of admission or allocation by the clinician, at high risk of bias. We judged studies that did not provide details on the method of sequence generation to be at unclear risk of bias. </p> </section> <section id="CD009504-sec-0054"> <h5 class="title">2. Allocation concealment</h5> <p>We rated studies that used adequate methods to conceal the randomisation, such as central allocation or sequentially‐numbered and identical‐looking drug containers, as having low risk of bias for this domain. Inadequate methods of concealment referred to methods by which clinicians or participants were able to foresee which group they were assigned to, such as using an open allocation schedule, and we judged them to be at high risk of bias. We rated studies that did not provide details on the method of concealment at unclear risk of bias. </p> </section> <section id="CD009504-sec-0055"> <h5 class="title">3. Blinding of participants, clinicians and outcome assessors</h5> <p>Blinding of participants, clinicians and outcome assessors were each assessed separately.</p> <p>With regard to participant blinding, we judged adequate blinding to have been achieved if the study reported that the placebo tablets were identical in appearance, and rated them at low risk of bias. We judged studies that reported that placebo tablets were not identical to bupropion, or unblinded studies, to be at high risk of bias. Where blinding was not reported, we rated the studies at unclear risk of bias. </p> <p>We judged adequate blinding for clinicians and outcome assessors to have been achieved if the study explicitly reported that these persons were blinded, and rated them at low risk of bias on the separate blinding domains. We judged unblinded studies to be at high risk of bias. Where this was not reported, we rated studies at unclear risk of bias for these domains. </p> </section> <section id="CD009504-sec-0056"> <h5 class="title">4. Incomplete outcome data</h5> <p>For this domain, we assessed the completeness of outcome data. We judged studies to be at low risk of bias if attrition was clearly reported, if it was balanced between the groups, and if it was judged not to be related to the study outcome. We also rated the study at low risk of bias if all participants that were randomised were included in the analysis. We accepted imputations in case of missing values. We assigned a high risk of bias for studies where we judged the reason for missing data to be related to the study outcome. This also applied to studies that analysed a subset of randomised participants; for example, only those participants that took at least one dose of medication or only those that attended the first follow‐up appointment. We considered imputation by last observation carried forward (LOCF) to be at high risk of bias, as it fails to acknowledge uncertainty in the imputed values and results; typically confidence intervals (CIs) are too narrow (<a href="./references#CD009504-bbs2-0056" title="HigginsJPT , AltmanDG , SterneJAC , editor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We rated studies that did not provide sufficient details on attrition, exclusions or methods of imputing missing values to permit judgement as being at unclear risk of bias. </p> </section> <section id="CD009504-sec-0057"> <h5 class="title">5. Selective reporting</h5> <p>We rated studies for which a protocol was available, and from which it was clear that the published reports contained all expected outcomes, at low risk of bias for this domain. We judged studies with unexplained differences in reported outcomes between protocol and study report to be at high risk of bias. Where we could not locate the protocol, we could make no assessment and judged the risk of bias to be unclear. </p> </section> <section id="CD009504-sec-0058"> <h5 class="title">6. Other bias</h5> <p>No other potential sources of bias were assessed. However, for each study, we noted whether or not the study was funded by the pharmaceutical industry. This information is reported in the <a href="./references#CD009504-sec-0156" title="">Characteristics of included studies</a> tables. </p> </section> </section> <section id="CD009504-sec-0059"> <h4 class="title">Measures of treatment effect</h4> <section id="CD009504-sec-0060"> <h5 class="title">Continuous outcomes</h5> <p>For continuous outcomes (e.g. change in severity of ADHD symptoms) measured identically across studies, we summarised data by calculating a mean difference (MD) and 95% confidence interval (CI). If the same continuous outcome was measured differently across studies, we calculated an overall standardised mean difference (SMD) and 95% CI, using Hedge's <i>g</i> (<a href="./references#CD009504-bbs2-0029" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). </p> </section> <section id="CD009504-sec-0061"> <h5 class="title">Dichotomous outcomes</h5> <p>For dichotomous outcomes (e.g. the proportion of participants achieving a significant clinical improvement), we summarised data by calculating the risk ratio (RR) with a 95% CI. </p> </section> </section> <section id="CD009504-sec-0062"> <h4 class="title">Unit of analysis issues</h4> <section id="CD009504-sec-0063"> <h5 class="title">Multiple‐arm trials</h5> <p>We performed pair‐wise comparisons, selecting 'placebo' versus 'bupropion' as being relevant to this systematic review. </p> <p>Additional methods described in the protocol (<a href="./references#CD009504-bbs2-0117" title="VerbeeckW , BekkeringGE , Van denNoortgateW . Bupropion for Attention Deficit Hyperactivity Disorder (ADHD) in adults. Cochrane Database of Systematic Reviews2011, Issue 12. [DOI: 10.1002/14651858.CD009504; Art. No.: CD009504] ">Verbeeck 2011</a>), but not used in this review are summarised in additional <a href="#CD009504-tbl-0002">Table 1</a>. </p> </section> </section> <section id="CD009504-sec-0064"> <h4 class="title">Dealing with missing data</h4> <p>In the first instance, we contacted authors with a request to supply data missing from included studies. If authors were not able or willing to supply the data, we imputed missing standard deviations by replacement values. The replacement value was the mean of the standard deviations of other studies in the analysis that used the same dependent variable, provided that the outcomes were measured identically. We anticipated conducting a <a href="#CD009504-sec-0070">Sensitivity analysis</a> to assess how sensitive our conclusions were to these replacements. We did not impute missing mean values. </p> </section> <section id="CD009504-sec-0065"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical heterogeneity by comparing the distribution of important participant factors between studies (such as treatment type, co‐interventions, participant characteristics, ADHD subtype), and discussed the impact of this on the findings. We did not assess methodological heterogeneity in this review, due to poor reporting of methodology. </p> <p>We assessed statistical heterogeneity by examining the I<sup>2</sup> statistic (<a href="./references#CD009504-bbs2-0029" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>; <a href="./references#CD009504-bbs2-0055" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [DOI: 10.1136/bmj.327.7414.557] ">Higgins 2003</a>), a measure which describes approximately the proportion of variation in point estimates that is due to heterogeneity rather than sampling error. We also employed a Chi<sup>2</sup> test of homogeneity to determine the strength of evidence that heterogeneity was genuine. </p> </section> <section id="CD009504-sec-0066"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not identify sufficient studies to conduct an assessment of reporting bias. Our plans for such assessment are reported in the protocol (<a href="./references#CD009504-bbs2-0117" title="VerbeeckW , BekkeringGE , Van denNoortgateW . Bupropion for Attention Deficit Hyperactivity Disorder (ADHD) in adults. Cochrane Database of Systematic Reviews2011, Issue 12. [DOI: 10.1002/14651858.CD009504; Art. No.: CD009504] ">Verbeeck 2011</a>), and described in additional <a href="#CD009504-tbl-0002">Table 1</a>. </p> </section> <section id="CD009504-sec-0067"> <h4 class="title">Data synthesis</h4> <p>We conducted meta‐analyses when at least two studies reported on similar interventions in respect of dosage, frequency and duration, and when suitable data were presented. We expected fewer than 10 studies in the analyses. We used a fixed‐effect model to pool the results because when there are few studies between‐study variance estimates may be very unreliable, and statistical inferences based on random‐effects models may be more flawed than estimates based on a fixed‐effect model (<a href="./references#CD009504-bbs2-0100" title="Van denNoortgateW , OnghenaP . Multilevel meta‐analysis: a comparison with traditional meta‐analytical procedures. Educational and Psychological Measurement2003;63(5):765‐90. [DOI: 10.1177/0013164403251027] ">Van den Noortgate 2003</a>). We used the inverse variance method to pool data from continuous outcomes, and the Mantel‐Haenszel method to pool data from dichotomous outcomes, as this method has been shown to have better statistical properties when data are sparse (<a href="./references#CD009504-bbs2-0029" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>), as is the case in this review. Where meta‐analysis was not possible, we provided a narrative description of the results and conclusions. </p> <section id="CD009504-sec-0068"> <h5 class="title">'Summary of findings' table</h5> <p>We produced <a href="./full#CD009504-tbl-0001">summary of findings Table for the main comparison</a> in which we report all <a href="#CD009504-sec-0044">Primary outcomes</a>. This table presents an overview of both the results and the quality of evidence. The basis for the assumed risk was the median control group risk across studies. We based the corresponding risk (and its 95% CI) on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). We assessed the quality of the evidence using the GRADE approach and associated criteria (<a href="./references#CD009504-bbs2-0049" title="GuyattGH , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. [DOI: 10.1016/j.jclinepi.2010.04.026; PUBMED: 21195583] ">Guyatt 2011a</a>). In this approach, RCTs start as high‐quality evidence but are downgraded by one, two or three levels (to moderate‐, low‐ and very low‐quality evidence), depending on the presence of the following five factors. </p> <p> <ol id="CD009504-list-0010"> <li> <p>Study limitations. We assessed important study design limitations, such as failure to conceal allocation, failure to blind, loss to follow‐up and failure to appropriately consider the intention to‐treat principle, using the Cochrane 'Risk of bias' tool (<a href="./references#CD009504-bbs2-0056" title="HigginsJPT , AltmanDG , SterneJAC , editor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> </li> <li> <p>Imprecision. We judged precision as adequate if the 95% CI excluded a RR of 1.00, and the total number of events or participants exceeded the optimal information size (OIS) criterion. We rated precision as inadequate if the 95% CI included appreciable benefit or harm (we used an RR of under 0.75 or over 1.25), even if the OIS criterion was met (<a href="./references#CD009504-bbs2-0050" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence ‐ imprecision. Journal of Clinical Epidemiology2011;64(12):1283‐93. [DOI: 10.1016/j.jclinepi.2011.01.012; PUBMED: 21839614] ">Guyatt 2011b</a>). </p> </li> <li> <p>Inconsistency of results. We assessed inconsistency of results using four criteria (1) point estimates varied widely across studies; (2) CIs showed minimal or no overlap; (3) the statistical test for heterogeneity, which tests the null hypothesis that all studies in a meta‐analysis have the same underlying magnitude of effect, showed a low P value; and (4) the I<sup>2</sup> was large (<a href="./references#CD009504-bbs2-0051" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 7. Rating the quality of evidence: inconsistency. Journal of Clinical Epidemiology2011;64(12):1294‐1302. [DOI: 10.1016/j.jclinepi.2011.03.017; PUBMED: 21803546] ">Guyatt 2011c</a>). </p> </li> <li> <p>Indirectness of evidence. We assessed whether the studies directly compared the intervention of interest delivered to the populations in which we were interested and measured the outcomes important to participants (<a href="./references#CD009504-bbs2-0052" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 8. Rating the quality of evidence ‐ indirectness. Journal of Clinical Epidemiology2011;64(12):1303‐10. [DOI: 10.1016/j.jclinepi.2011.04.014; PUBMED: 21802903] ">Guyatt 2011d</a>). </p> </li> <li> <p>Publication bias. There were too few studies in the review to be able to assess small‐study effects statistically. </p> </li> </ol> </p> <p>We report the ratings for the overall quality of evidence for each outcome and the reasons for downgrading in <a href="./full#CD009504-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> </section> <section id="CD009504-sec-0069"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We did not conduct subgroup analyses on the type of drug‐release formulation, because all studies assessed a long‐acting version of bupropion, or on dose of study drug, because the actual study dose was not reported. We describe these analyses, which have been archived for use in future updates of this review, in <a href="#CD009504-tbl-0002">Table 1</a> and in our protocol (<a href="./references#CD009504-bbs2-0117" title="VerbeeckW , BekkeringGE , Van denNoortgateW . Bupropion for Attention Deficit Hyperactivity Disorder (ADHD) in adults. Cochrane Database of Systematic Reviews2011, Issue 12. [DOI: 10.1002/14651858.CD009504; Art. No.: CD009504] ">Verbeeck 2011</a>). </p> </section> <section id="CD009504-sec-0070"> <h4 class="title">Sensitivity analysis</h4> <p>We performed the following three sensitivity analyses on our <a href="#CD009504-sec-0044">Primary outcomes</a>. </p> <p> <ol id="CD009504-list-0011"> <li> <p>The impact of including studies of participants with potential comorbid disorders, by analysing only those studies where the presence of a comorbid disorder was an exclusion criterion. </p> </li> <li> <p>The impact of combining self‐rated and clinician‐rated ADHD scales, by analysing only those studies that used clinician‐rated ADHD scales. </p> </li> <li> <p>The impact of using fixed‐effect meta‐analyses, by comparing the results of fixed‐effect versus random‐effects models. See <a href="#CD009504-sec-0154">Differences between protocol and review</a>. </p> </li> </ol> </p> <p>In <a href="#CD009504-tbl-0002">Table 1</a>, we summarise additional sensitivity analyses that we had planned to perform, to assess whether findings would be sensitive to restricting the analyses to studies judged to be at low risk of bias (<a href="./references#CD009504-bbs2-0117" title="VerbeeckW , BekkeringGE , Van denNoortgateW . Bupropion for Attention Deficit Hyperactivity Disorder (ADHD) in adults. Cochrane Database of Systematic Reviews2011, Issue 12. [DOI: 10.1002/14651858.CD009504; Art. No.: CD009504] ">Verbeeck 2011</a>). However, we were unable to conduct these analyses because we considered none of the studies at low risk of bias for some characteristics (based on assessment sequence generation and allocation concealment, financial support and affiliations with industry), and we considered all studies to be at low risk of bias for other characteristics (i.e. data imputation and unstandardised instruments were not used in any of the studies). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009504-sec-0071" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009504-sec-0071"></div> <section id="CD009504-sec-0072"> <h3 class="title">Description of studies</h3> <section id="CD009504-sec-0073"> <h4 class="title">Results of the search</h4> <p>The database searches yielded 2235 records. After de‐duplication, we screened the titles and abstracts of 1645 records and discarded 1633 as irrelevant. We obtained the full‐text reports of the 12 remaining records and assessed these against our inclusion criteria (<a href="#CD009504-sec-0039">Criteria for considering studies for this review</a>). We excluded four irrelevant reports, and formally excluded one report with a reason (<a href="#CD009504-sec-0083">Excluded studies</a>). We included six studies (from seven reports) in this review (<a href="#CD009504-sec-0074">Included studies</a>). See <a href="#CD009504-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD009504-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009504-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD009504-sec-0074"> <h4 class="title">Included studies</h4> <p>Please see the <a href="./references#CD009504-sec-0156" title="">Characteristics of included studies</a> tables for more details. </p> <section id="CD009504-sec-0075"> <h5 class="title">Setting and location</h5> <p>Five studies were conducted in the USA (<a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>; <a href="./references#CD009504-bbs2-0003" title="LevinFR , EvansSM , BrooksDJ , KalbagAS , GarawiF , NunesEV . Treatment of methadone‐maintained patients with adult ADHD: double‐blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence2006;81(2):137‐48. [DOI: 10.1016/j.drugalcdep.2005.06.012; PUBMED: 16102908] ">Levin 2006</a>; <a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>; <a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>) and one in Iran (<a href="./references#CD009504-bbs2-0001" title="HamediM , MohammadiM , GhaleihaA , KeshavarziZ , JafariniaM , KeramatfarR , et al. Bupropion in adults with attention‐deficit/hyperactivity disorder: a randomized double‐blinded study. Acta Medica Iranica2014;52(9):675‐80. [PUBMED: 25325205] ">Hamedi 2014</a>). Four studies recruited cases from one location or treatment centre (<a href="./references#CD009504-bbs2-0001" title="HamediM , MohammadiM , GhaleihaA , KeshavarziZ , JafariniaM , KeramatfarR , et al. Bupropion in adults with attention‐deficit/hyperactivity disorder: a randomized double‐blinded study. Acta Medica Iranica2014;52(9):675‐80. [PUBMED: 25325205] ">Hamedi 2014</a>; <a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>; <a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>; <a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>), and two studies recruited cases from multiple centres (<a href="./references#CD009504-bbs2-0003" title="LevinFR , EvansSM , BrooksDJ , KalbagAS , GarawiF , NunesEV . Treatment of methadone‐maintained patients with adult ADHD: double‐blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence2006;81(2):137‐48. [DOI: 10.1016/j.drugalcdep.2005.06.012; PUBMED: 16102908] ">Levin 2006</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>). </p> </section> <section id="CD009504-sec-0076"> <h5 class="title">Study design</h5> <p>All included studies were RCTs.</p> </section> <section id="CD009504-sec-0077"> <h5 class="title">Participants</h5> <p>The six included studies randomised 438 participants (<a href="./references#CD009504-bbs2-0001" title="HamediM , MohammadiM , GhaleihaA , KeshavarziZ , JafariniaM , KeramatfarR , et al. Bupropion in adults with attention‐deficit/hyperactivity disorder: a randomized double‐blinded study. Acta Medica Iranica2014;52(9):675‐80. [PUBMED: 25325205] ">Hamedi 2014</a>; <a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>; <a href="./references#CD009504-bbs2-0003" title="LevinFR , EvansSM , BrooksDJ , KalbagAS , GarawiF , NunesEV . Treatment of methadone‐maintained patients with adult ADHD: double‐blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence2006;81(2):137‐48. [DOI: 10.1016/j.drugalcdep.2005.06.012; PUBMED: 16102908] ">Levin 2006</a>; <a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>; <a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>). Of these, 270 (62%) were men. The mean age of the groups ranged between 32.2 years (<a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>) and 41.4 years (<a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>). </p> <p>Three of the six studies reported race distribution (<a href="./references#CD009504-bbs2-0001" title="HamediM , MohammadiM , GhaleihaA , KeshavarziZ , JafariniaM , KeramatfarR , et al. Bupropion in adults with attention‐deficit/hyperactivity disorder: a randomized double‐blinded study. Acta Medica Iranica2014;52(9):675‐80. [PUBMED: 25325205] ">Hamedi 2014</a>; <a href="./references#CD009504-bbs2-0003" title="LevinFR , EvansSM , BrooksDJ , KalbagAS , GarawiF , NunesEV . Treatment of methadone‐maintained patients with adult ADHD: double‐blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence2006;81(2):137‐48. [DOI: 10.1016/j.drugalcdep.2005.06.012; PUBMED: 16102908] ">Levin 2006</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>). <a href="./references#CD009504-bbs2-0003" title="LevinFR , EvansSM , BrooksDJ , KalbagAS , GarawiF , NunesEV . Treatment of methadone‐maintained patients with adult ADHD: double‐blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence2006;81(2):137‐48. [DOI: 10.1016/j.drugalcdep.2005.06.012; PUBMED: 16102908] ">Levin 2006</a> included mainly white (39% and 42% for the two groups) and Hispanic participants (39% for the two groups) and a smaller proportion of black participants (21% and 18%). The study population of <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a> consisted of 88% white, 6% black and 4% American‐Hispanic participants. One study was performed in a Persian population (<a href="./references#CD009504-bbs2-0001" title="HamediM , MohammadiM , GhaleihaA , KeshavarziZ , JafariniaM , KeramatfarR , et al. Bupropion in adults with attention‐deficit/hyperactivity disorder: a randomized double‐blinded study. Acta Medica Iranica2014;52(9):675‐80. [PUBMED: 25325205] ">Hamedi 2014</a>). Although these studies reported the ethnic origin of the included participant sample, the influence of race on responsiveness to pharmacotherapy was not further explored. </p> <p>Two studies reported ADHD subtype (<a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>). The main subtype in the <a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a> study was the inattentive subtype (58% of the total) and the main subtype in the <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a> study was the combined subtype (68% and 58% for the two treatment groups). </p> <p>Four studies excluded participants with psychiatric comorbidity (<a href="./references#CD009504-bbs2-0001" title="HamediM , MohammadiM , GhaleihaA , KeshavarziZ , JafariniaM , KeramatfarR , et al. Bupropion in adults with attention‐deficit/hyperactivity disorder: a randomized double‐blinded study. Acta Medica Iranica2014;52(9):675‐80. [PUBMED: 25325205] ">Hamedi 2014</a>; <a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>; <a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>), one study was unclear about this (<a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>), and another study included participants with opioid dependency (<a href="./references#CD009504-bbs2-0003" title="LevinFR , EvansSM , BrooksDJ , KalbagAS , GarawiF , NunesEV . Treatment of methadone‐maintained patients with adult ADHD: double‐blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence2006;81(2):137‐48. [DOI: 10.1016/j.drugalcdep.2005.06.012; PUBMED: 16102908] ">Levin 2006</a>). </p> <p>For a detailed description of participant characteristics, see <a href="./references#CD009504-sec-0156" title="">Characteristics of included studies</a>. </p> </section> <section id="CD009504-sec-0078"> <h5 class="title">Intervention</h5> <p>All studies compared a long‐acting version of bupropion with placebo. Two studies also included a comparison with an active intervention (methylphenidate) (<a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>; <a href="./references#CD009504-bbs2-0003" title="LevinFR , EvansSM , BrooksDJ , KalbagAS , GarawiF , NunesEV . Treatment of methadone‐maintained patients with adult ADHD: double‐blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence2006;81(2):137‐48. [DOI: 10.1016/j.drugalcdep.2005.06.012; PUBMED: 16102908] ">Levin 2006</a>). Five studied doses of bupropion ranging from up to 300 mg to up to 450 mg per day; the average dose in the <a href="./references#CD009504-bbs2-0001" title="HamediM , MohammadiM , GhaleihaA , KeshavarziZ , JafariniaM , KeramatfarR , et al. Bupropion in adults with attention‐deficit/hyperactivity disorder: a randomized double‐blinded study. Acta Medica Iranica2014;52(9):675‐80. [PUBMED: 25325205] ">Hamedi 2014</a> study was 150 mg per day. Study intervention length varied from six to 10 weeks, with a mean of 7.2 weeks. </p> </section> <section id="CD009504-sec-0079"> <h5 class="title">Outcomes and outcome measures</h5> <p>Five of the six studies reported scores on the severity of ADHD, but the outcome measures differed between studies (<a href="./references#CD009504-bbs2-0001" title="HamediM , MohammadiM , GhaleihaA , KeshavarziZ , JafariniaM , KeramatfarR , et al. Bupropion in adults with attention‐deficit/hyperactivity disorder: a randomized double‐blinded study. Acta Medica Iranica2014;52(9):675‐80. [PUBMED: 25325205] ">Hamedi 2014</a>; <a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>; <a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>; <a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>). <a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a> reported the Wender‐Reimherr Adult Attention Deficit Disorder Scale (WRAADS; <a href="./references#CD009504-bbs2-0070" title="Marchant , BK , ReimherrFW , RobisonD , RobisonRJ , WenderPH . Psychometric properties of the Wender‐Reimherr Adult Attention Deficit Disorder Scale. Psychological AssessmentSept 2013;25(3):942‐50. [DOI: 10.1037/a0032797; PUBMED: 23647041] ">Marchant 2013</a>), a clinician‐rated scale with scores ranging from 0 to 28. The two Wilens studies used the clinician‐rated ADHD Symptom Checklist (<a href="./references#CD009504-bbs2-0033" title="DuPaulGJ . The ADHD Rating Scale: Normative Data, Reliability, and Validity. Worchester (MA): University of Massachusetts Medical Center, 1990. ">DuPaul 1990</a>), with scores ranging from 0 to 54 (<a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>). <a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a> used the participant‐rated ADHD Symptom Checklist ‐ Severity Scale (<a href="./references#CD009504-bbs2-0017" title="BarkleyRA . Attention‐Deficit Hyperactivity Disorder: a Handbook for Diagnosis and Treatment. New York: Guilford Press, 1990. ">Barkley 1990</a>), with scores ranging between 0 and 42. <a href="./references#CD009504-bbs2-0001" title="HamediM , MohammadiM , GhaleihaA , KeshavarziZ , JafariniaM , KeramatfarR , et al. Bupropion in adults with attention‐deficit/hyperactivity disorder: a randomized double‐blinded study. Acta Medica Iranica2014;52(9):675‐80. [PUBMED: 25325205] ">Hamedi 2014</a> used the self‐report screening form from the Conners' Adult ADHD Rating Scales (CAARS) scales (<a href="./references#CD009504-bbs2-0026" title="DeGeorge MaceyK . Book review. Conners' adult ADHD rating scales (CAARS). Archives of Clinical Neuropsychology2003;18(4):431‐7. [DOI: 10.1016/S0887‐6177(03)00021‐0] ">Conners 2003</a>). Based on the mean scores in the two groups, we assumed that the short version was used, with scores ranging between 0 and 48. </p> <p>All scales are scored in the same direction, with a higher score indicating more symptoms.</p> <p>Five studies reported the proportion of participants achieving a significant clinical improvement (<a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>; <a href="./references#CD009504-bbs2-0003" title="LevinFR , EvansSM , BrooksDJ , KalbagAS , GarawiF , NunesEV . Treatment of methadone‐maintained patients with adult ADHD: double‐blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence2006;81(2):137‐48. [DOI: 10.1016/j.drugalcdep.2005.06.012; PUBMED: 16102908] ">Levin 2006</a>; <a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>; <a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>), defined as a score of one or two on the Clinical Global Impression‐Improvement (CGI‐I) scale (<a href="./references#CD009504-bbs2-0080" title="National Institute of Mental Health. CGI (Clinical Global Impression Scale). Psychopharmacology Bulletin1985;21:839‐44. ">NIMH 1984</a>). Four studies also reported this outcome using a reduction of at least 30% in the severity of ADHD symptoms. </p> <p>Three studies reported the number of participants withdrawn due to any event (<a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>; <a href="./references#CD009504-bbs2-0003" title="LevinFR , EvansSM , BrooksDJ , KalbagAS , GarawiF , NunesEV . Treatment of methadone‐maintained patients with adult ADHD: double‐blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence2006;81(2):137‐48. [DOI: 10.1016/j.drugalcdep.2005.06.012; PUBMED: 16102908] ">Levin 2006</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>). One study reported that “there was no evidence of adverse effects leading to study withdrawal” (<a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>), and another study reported adverse events using another outcome (<a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>), i.e. the number of participants with adverse effects and the number of participants that lowered the dose of their medication due to adverse effects. </p> </section> <section id="CD009504-sec-0080"> <h5 class="title">Attrition</h5> <p>Five studies reported retention rates (<a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>; <a href="./references#CD009504-bbs2-0003" title="LevinFR , EvansSM , BrooksDJ , KalbagAS , GarawiF , NunesEV . Treatment of methadone‐maintained patients with adult ADHD: double‐blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence2006;81(2):137‐48. [DOI: 10.1016/j.drugalcdep.2005.06.012; PUBMED: 16102908] ">Levin 2006</a>; <a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>; <a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>). The retention rates in the bupropion groups varied from 69.7% (<a href="./references#CD009504-bbs2-0003" title="LevinFR , EvansSM , BrooksDJ , KalbagAS , GarawiF , NunesEV . Treatment of methadone‐maintained patients with adult ADHD: double‐blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence2006;81(2):137‐48. [DOI: 10.1016/j.drugalcdep.2005.06.012; PUBMED: 16102908] ">Levin 2006</a>) to 90.5% (<a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>). The retention rates of the placebo groups varied between 75.0% (<a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>) and 100% (<a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>). <a href="./references#CD009504-bbs2-0001" title="HamediM , MohammadiM , GhaleihaA , KeshavarziZ , JafariniaM , KeramatfarR , et al. Bupropion in adults with attention‐deficit/hyperactivity disorder: a randomized double‐blinded study. Acta Medica Iranica2014;52(9):675‐80. [PUBMED: 25325205] ">Hamedi 2014</a> was unclear about the number of participants that were dropped during the trial, </p> </section> <section id="CD009504-sec-0081"> <h5 class="title">Compliance</h5> <p>Compliance was measured and reported in various ways. <a href="./references#CD009504-bbs2-0003" title="LevinFR , EvansSM , BrooksDJ , KalbagAS , GarawiF , NunesEV . Treatment of methadone‐maintained patients with adult ADHD: double‐blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence2006;81(2):137‐48. [DOI: 10.1016/j.drugalcdep.2005.06.012; PUBMED: 16102908] ">Levin 2006</a> gave self‐reported compliance rates of 0.83 for placebo and 0.91 for bupropion. Compliance rates in the <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a> study were 0.989 and 0.998 for bupropion and placebo groups, respectively. <a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a> reported all participants to be compliant based on medication logs and pill counts. <a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a> measured compliance using pill‐counting but no results were reported. The remaining studies were unclear whether compliance was measured (<a href="./references#CD009504-bbs2-0001" title="HamediM , MohammadiM , GhaleihaA , KeshavarziZ , JafariniaM , KeramatfarR , et al. Bupropion in adults with attention‐deficit/hyperactivity disorder: a randomized double‐blinded study. Acta Medica Iranica2014;52(9):675‐80. [PUBMED: 25325205] ">Hamedi 2014</a>; <a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>) </p> </section> <section id="CD009504-sec-0082"> <h5 class="title">Study funding</h5> <p>Four studies were funded by industry (<a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>; <a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>; <a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>), and two studies were publicly funded (<a href="./references#CD009504-bbs2-0001" title="HamediM , MohammadiM , GhaleihaA , KeshavarziZ , JafariniaM , KeramatfarR , et al. Bupropion in adults with attention‐deficit/hyperactivity disorder: a randomized double‐blinded study. Acta Medica Iranica2014;52(9):675‐80. [PUBMED: 25325205] ">Hamedi 2014</a>; <a href="./references#CD009504-bbs2-0003" title="LevinFR , EvansSM , BrooksDJ , KalbagAS , GarawiF , NunesEV . Treatment of methadone‐maintained patients with adult ADHD: double‐blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence2006;81(2):137‐48. [DOI: 10.1016/j.drugalcdep.2005.06.012; PUBMED: 16102908] ">Levin 2006</a>). In one of the publicly‐funded studies (<a href="./references#CD009504-bbs2-0003" title="LevinFR , EvansSM , BrooksDJ , KalbagAS , GarawiF , NunesEV . Treatment of methadone‐maintained patients with adult ADHD: double‐blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence2006;81(2):137‐48. [DOI: 10.1016/j.drugalcdep.2005.06.012; PUBMED: 16102908] ">Levin 2006</a>), the first author was a consultant for several pharmaceutical companies and also received investigator‐driven funding from two companies, however none of these companies manufacture bupropion. </p> </section> </section> <section id="CD009504-sec-0083"> <h4 class="title">Excluded studies</h4> <p>We excluded one study from the review because it was performed in a non‐adult population (See <a href="./references#CD009504-sec-0157" title="">Characteristics of excluded studies</a>; <a href="./references#CD009504-bbs1-0002" title="">Excluded studies</a>). </p> </section> </section> <section id="CD009504-sec-0084"> <h3 class="title">Risk of bias in included studies</h3> <p>We present a comprehensive description of the risk of bias of each included study in the 'Risk of bias' tables, beneath the <a href="./references#CD009504-sec-0156" title="">Characteristics of included studies</a> tables, with information summarised in <a href="#CD009504-fig-0002">Figure 2</a>. We rated approximately 75% of all 'Risk of bias' items as unclear, reflecting poor reporting of methodology and outcomes of trials on the effectiveness of bupropion. </p> <div class="figure" id="CD009504-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD009504-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD009504-sec-0085"> <h4 class="title">Allocation</h4> <section id="CD009504-sec-0086"> <h5 class="title">Random sequence generation</h5> <p>None of the included studies reported details on how the random sequence was generated, so we scored all studies as being at unclear risk of bias for this domain (<a href="./references#CD009504-bbs2-0001" title="HamediM , MohammadiM , GhaleihaA , KeshavarziZ , JafariniaM , KeramatfarR , et al. Bupropion in adults with attention‐deficit/hyperactivity disorder: a randomized double‐blinded study. Acta Medica Iranica2014;52(9):675‐80. [PUBMED: 25325205] ">Hamedi 2014</a>; <a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>; <a href="./references#CD009504-bbs2-0003" title="LevinFR , EvansSM , BrooksDJ , KalbagAS , GarawiF , NunesEV . Treatment of methadone‐maintained patients with adult ADHD: double‐blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence2006;81(2):137‐48. [DOI: 10.1016/j.drugalcdep.2005.06.012; PUBMED: 16102908] ">Levin 2006</a>; <a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>; <a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>). </p> </section> <section id="CD009504-sec-0087"> <h5 class="title">Allocation concealment</h5> <p>Only one study (<a href="./references#CD009504-bbs2-0001" title="HamediM , MohammadiM , GhaleihaA , KeshavarziZ , JafariniaM , KeramatfarR , et al. Bupropion in adults with attention‐deficit/hyperactivity disorder: a randomized double‐blinded study. Acta Medica Iranica2014;52(9):675‐80. [PUBMED: 25325205] ">Hamedi 2014</a>) reported an adequate method of allocation concealment leading to a judgement of low risk of bias. We score the remaining studies as being at unclear risk of bias for this domain (<a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>; <a href="./references#CD009504-bbs2-0003" title="LevinFR , EvansSM , BrooksDJ , KalbagAS , GarawiF , NunesEV . Treatment of methadone‐maintained patients with adult ADHD: double‐blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence2006;81(2):137‐48. [DOI: 10.1016/j.drugalcdep.2005.06.012; PUBMED: 16102908] ">Levin 2006</a>; <a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>; <a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>). </p> </section> </section> <section id="CD009504-sec-0088"> <h4 class="title">Blinding</h4> <p>We judged blinding of participants to be adequately addressed in three studies; two because these studies stated that placebo tablets were identical in appearance to bupropion tablets (<a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>), and one because it stated that all people involved in the study were blinded (<a href="./references#CD009504-bbs2-0001" title="HamediM , MohammadiM , GhaleihaA , KeshavarziZ , JafariniaM , KeramatfarR , et al. Bupropion in adults with attention‐deficit/hyperactivity disorder: a randomized double‐blinded study. Acta Medica Iranica2014;52(9):675‐80. [PUBMED: 25325205] ">Hamedi 2014</a>). We judged blinding as unclear for the remaining three studies, as no details on blinding were given (<a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>; <a href="./references#CD009504-bbs2-0003" title="LevinFR , EvansSM , BrooksDJ , KalbagAS , GarawiF , NunesEV . Treatment of methadone‐maintained patients with adult ADHD: double‐blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence2006;81(2):137‐48. [DOI: 10.1016/j.drugalcdep.2005.06.012; PUBMED: 16102908] ">Levin 2006</a>; <a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>). </p> <p>Blinding of clinicians and assessors was not discussed in five studies and hence we rated these studies at unclear risk of bias (<a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>; <a href="./references#CD009504-bbs2-0003" title="LevinFR , EvansSM , BrooksDJ , KalbagAS , GarawiF , NunesEV . Treatment of methadone‐maintained patients with adult ADHD: double‐blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence2006;81(2):137‐48. [DOI: 10.1016/j.drugalcdep.2005.06.012; PUBMED: 16102908] ">Levin 2006</a>; <a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>; <a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>). We rated one study (<a href="./references#CD009504-bbs2-0001" title="HamediM , MohammadiM , GhaleihaA , KeshavarziZ , JafariniaM , KeramatfarR , et al. Bupropion in adults with attention‐deficit/hyperactivity disorder: a randomized double‐blinded study. Acta Medica Iranica2014;52(9):675‐80. [PUBMED: 25325205] ">Hamedi 2014</a>) at low risk of bias, as it stated that all people involved in the study were blind to assignments. </p> </section> <section id="CD009504-sec-0089"> <h4 class="title">Incomplete outcome data</h4> <p>We rated five studies as having a high risk of bias for this domain; four because they did not perform intention‐to‐treat analyses (<a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>; <a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>; <a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>), and one because they reported that some participants were dropped because they could not tolerate the drug, without reporting the number of dropouts (<a href="./references#CD009504-bbs2-0001" title="HamediM , MohammadiM , GhaleihaA , KeshavarziZ , JafariniaM , KeramatfarR , et al. Bupropion in adults with attention‐deficit/hyperactivity disorder: a randomized double‐blinded study. Acta Medica Iranica2014;52(9):675‐80. [PUBMED: 25325205] ">Hamedi 2014</a>). The remaining study reported both the numbers of dropouts in each group as well as the reasons for dropout (<a href="./references#CD009504-bbs2-0003" title="LevinFR , EvansSM , BrooksDJ , KalbagAS , GarawiF , NunesEV . Treatment of methadone‐maintained patients with adult ADHD: double‐blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence2006;81(2):137‐48. [DOI: 10.1016/j.drugalcdep.2005.06.012; PUBMED: 16102908] ">Levin 2006</a>). However, we judged this study to be at unclear risk of bias because of the high numbers of participants that dropped out (10/33 in the bupropion group and 8/33 in the placebo group). </p> </section> <section id="CD009504-sec-0090"> <h4 class="title">Selective reporting</h4> <p>We rated all studies at unclear risk of reporting bias, as we were unable to ascertain whether all measured outcomes were reported (<a href="./references#CD009504-bbs2-0001" title="HamediM , MohammadiM , GhaleihaA , KeshavarziZ , JafariniaM , KeramatfarR , et al. Bupropion in adults with attention‐deficit/hyperactivity disorder: a randomized double‐blinded study. Acta Medica Iranica2014;52(9):675‐80. [PUBMED: 25325205] ">Hamedi 2014</a>; <a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>; <a href="./references#CD009504-bbs2-0003" title="LevinFR , EvansSM , BrooksDJ , KalbagAS , GarawiF , NunesEV . Treatment of methadone‐maintained patients with adult ADHD: double‐blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence2006;81(2):137‐48. [DOI: 10.1016/j.drugalcdep.2005.06.012; PUBMED: 16102908] ">Levin 2006</a>; <a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>; <a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>). </p> </section> </section> <section id="CD009504-sec-0091"> <h3 class="title" id="CD009504-sec-0091">Effects of interventions</h3> <p>See: <a href="./full#CD009504-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <section id="CD009504-sec-0092"> <h4 class="title">Comparison: Bupropion versus placebo</h4> <section id="CD009504-sec-0093"> <h5 class="title">Primary outcomes</h5> <section id="CD009504-sec-0094"> <h6 class="title">1. Efficacy outcomes</h6> <section id="CD009504-sec-0095"> <p><b>A. Changes in the severity of ADHD symptoms from baseline</b></p> <p>Five studies reported the severity of ADHD symptoms (<a href="./references#CD009504-bbs2-0001" title="HamediM , MohammadiM , GhaleihaA , KeshavarziZ , JafariniaM , KeramatfarR , et al. Bupropion in adults with attention‐deficit/hyperactivity disorder: a randomized double‐blinded study. Acta Medica Iranica2014;52(9):675‐80. [PUBMED: 25325205] ">Hamedi 2014</a>; <a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>; <a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>; <a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>). </p> <p>Three studies (129 participants) reported severity of ADHD at study completion (<a href="./references#CD009504-bbs2-0001" title="HamediM , MohammadiM , GhaleihaA , KeshavarziZ , JafariniaM , KeramatfarR , et al. Bupropion in adults with attention‐deficit/hyperactivity disorder: a randomized double‐blinded study. Acta Medica Iranica2014;52(9):675‐80. [PUBMED: 25325205] ">Hamedi 2014</a>; <a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>; <a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>). The pooled, fixed‐effect SMD between bupropion and placebo was ‐0.50 (95% confidence interval (CI) ‐0.86 to ‐0.15, I<sup>2</sup> = 0%, see <a href="./references#CD009504-fig-0007" title="">Analysis 1.1</a>; <a href="#CD009504-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD009504-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Bupropion versus placebo, outcome: 1.1 Severity of ADHD (at study completion)." data-id="CD009504-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Bupropion versus placebo, outcome: 1.1 Severity of ADHD (at study completion). </p> </div> </div> </div> <p>Two other studies reported mean change from baseline to study completion (<a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>). However, in the <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a> study, standard deviations were missing. We did not impute these standard deviations using the <a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a> study, as the outcomes were not measured in an identical way. <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a> reported better results for the bupropion group, while <a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a> found no difference between the groups. The results of these studies are reported in <a href="#CD009504-tbl-0003">Table 2</a>. </p> <div class="table" id="CD009504-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Results of individual studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome/scale</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Results for bupropion</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Results for placebo (P value for difference between groups)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐rated ADHD symptoms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐13.7 (SD 6.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐12.4 (SD 10.6) (P = 0.69)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global level of functioning</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean final value at study completion 57.5 (SD 8.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean final value at study completion 56.2 (SD 3.6) (P &gt; 0.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADHD Symptom Checklist (<a href="./references#CD009504-bbs2-0033" title="DuPaulGJ . The ADHD Rating Scale: Normative Data, Reliability, and Validity. Worchester (MA): University of Massachusetts Medical Center, 1990. ">DuPaul 1990</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean difference from baseline ‐12.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean difference ‐6.9 (P &lt; 0.001)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global level of functioning</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change from baseline 7.3 (SD 10.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0 (SD 8.0) (P = 0.035)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADHD: attention deficit hyperactivity disorder<br/> ID: identifier<br/> SD: standard deviation. </p> </div> </div> </section> <section id="CD009504-sec-0096"> <p><b>B. Proportion of participants achieving a significant clinical improvement</b></p> <p>Four studies (315 participants) reported the proportion of participants achieving a significant clinical improvement (<a href="./references#CD009504-bbs2-0003" title="LevinFR , EvansSM , BrooksDJ , KalbagAS , GarawiF , NunesEV . Treatment of methadone‐maintained patients with adult ADHD: double‐blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence2006;81(2):137‐48. [DOI: 10.1016/j.drugalcdep.2005.06.012; PUBMED: 16102908] ">Levin 2006</a>; <a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>; <a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>), using either the WRAADDS (<a href="./references#CD009504-bbs2-0070" title="Marchant , BK , ReimherrFW , RobisonD , RobisonRJ , WenderPH . Psychometric properties of the Wender‐Reimherr Adult Attention Deficit Disorder Scale. Psychological AssessmentSept 2013;25(3):942‐50. [DOI: 10.1037/a0032797; PUBMED: 23647041] ">Marchant 2013</a>), the ADHD Symptom Checklist (<a href="./references#CD009504-bbs2-0033" title="DuPaulGJ . The ADHD Rating Scale: Normative Data, Reliability, and Validity. Worchester (MA): University of Massachusetts Medical Center, 1990. ">DuPaul 1990</a>) or a participant‐rated scale (Adult ADHD Rating Scale (AARS); <a href="./references#CD009504-bbs2-0076" title="MurphyK , BarkleyRA . Prevalence of DSM‐IV symptoms of ADHD in adult licensed drivers: implications for clinical diagnosis. Journal of Attention Disorders1996;1(3):147‐61. [DOI: 10.1177/108705479600100303] ">Murphy 1996</a>). The pooled, fixed‐effect RR for achieving significant clinical improvement (% of participants) was 1.50 (95% CI 1.13 to 1.99, I<sup>2</sup> = 27%, see <a href="./references#CD009504-fig-0008" title="">Analysis 1.2</a>; <a href="#CD009504-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD009504-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Bupropion vs placebo, outcome: 1.1 Achievement of significant clinical improvement (% participants)." data-id="CD009504-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Bupropion vs placebo, outcome: 1.1 Achievement of significant clinical improvement (% participants). </p> </div> </div> </div> <p>Five studies (337 participants) assessed the effect of bupropion versus placebo by means of the CGI (at least one or two points on the CGI) (<a href="./references#CD009504-bbs2-0080" title="National Institute of Mental Health. CGI (Clinical Global Impression Scale). Psychopharmacology Bulletin1985;21:839‐44. ">NIMH 1984</a>). The pooled, fixed‐effect RR for achieving significant clinical improvement (% of participants) was 1.78 (95% CI 1.27 to 2.50, I<sup>2</sup> = 54%, see <a href="./references#CD009504-fig-0009" title="">Analysis 1.3</a>; <a href="#CD009504-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD009504-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Bupropion vs placebo, outcome: 1.3 Clinical Global Impression (CGI) ‐ improvement scale (% participants achieving at least 1 or 2 on CGI)." data-id="CD009504-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Bupropion vs placebo, outcome: 1.3 Clinical Global Impression (CGI) ‐ improvement scale (% participants achieving at least 1 or 2 on CGI). </p> </div> </div> </div> </section> </section> <section id="CD009504-sec-0097"> <h6 class="title">2. Adverse events: Proportion of participants withdrawn due to any adverse event (somatic or psychiatric) </h6> <p>Three studies (253 participants) reported the number of participants who withdrew due to any adverse events (<a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>; <a href="./references#CD009504-bbs2-0003" title="LevinFR , EvansSM , BrooksDJ , KalbagAS , GarawiF , NunesEV . Treatment of methadone‐maintained patients with adult ADHD: double‐blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence2006;81(2):137‐48. [DOI: 10.1016/j.drugalcdep.2005.06.012; PUBMED: 16102908] ">Levin 2006</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>). The pooled, fixed‐effect RR was 1.20 (95% CI 0.35 to 4.10, I<sup>2</sup> = 49%, see <a href="./references#CD009504-fig-0010" title="">Analysis 1.4</a>; <a href="#CD009504-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD009504-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Bupropion versus placebo, outcome: 1.4 Number of participants withdrawn due to adverse events." data-id="CD009504-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Bupropion versus placebo, outcome: 1.4 Number of participants withdrawn due to adverse events. </p> </div> </div> </div> <p>One study (<a href="./references#CD009504-bbs2-0001" title="HamediM , MohammadiM , GhaleihaA , KeshavarziZ , JafariniaM , KeramatfarR , et al. Bupropion in adults with attention‐deficit/hyperactivity disorder: a randomized double‐blinded study. Acta Medica Iranica2014;52(9):675‐80. [PUBMED: 25325205] ">Hamedi 2014</a>) reported that the maximum dose in their study was 150 mg a day, due to adverse events. Some cases were dropped due to side effects but the exact numbers were not reported. </p> </section> </section> <section id="CD009504-sec-0098"> <h5 class="title">Secondary outcomes</h5> <section id="CD009504-sec-0099"> <h6 class="title">1. Efficacy outcomes</h6> <section id="CD009504-sec-0100"> <p><b>A. Clinical impression</b></p> <p>No studies reported data on this outcome.</p> </section> <section id="CD009504-sec-0101"> <p><b>B Global level of functioning</b></p> <p>Two studies (<a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>) used the Global Assessment of Functioning (GAF) scale (<a href="./references#CD009504-bbs2-0046" title="GoldmanHH , SkodolAE , LaveTR . Revising axis V for DSM‐IV: a review of measures of social functioning. American Journal of Psychiatry1992;149(9):1148‐56. [DOI: 10.1176/ajp.149.9.1148; PUBMED: 1386964] ">Goldman 1992</a>). These were not pooled as <a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a> reported only the mean final values (at study completion), while <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a> reported mean change from baseline scores. <a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a> found no differences while <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a> reported an increased change from baseline in the group that received bupropion. The results of these studies are reported in <a href="#CD009504-tbl-0003">Table 2</a>. </p> </section> <section id="CD009504-sec-0102"> <p><b>C Social adjustment</b></p> <p>No studies reported data on this outcome.</p> </section> <section id="CD009504-sec-0103"> <p><b>D Depressive symptoms</b></p> <p>Two studies (184 participants) reported the mean change from baseline for depressive symptoms using the Hamilton Depression Rating Scale (HAM‐D; <a href="./references#CD009504-bbs2-0053" title="HamiltonM . A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry1960;23:56‐62. [10.1136/jnnp.23.1.56 PMID 14399272] ">Hamilton 1960</a>) (<a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>). The pooled, fixed‐effect MD between bupropion and placebo was 0.52 (95% CI ‐0.46 to 1.51, I<sup>2</sup> = 0%; see <a href="./references#CD009504-fig-0011" title="">Analysis 1.5</a>). </p> <p><a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a> did not quantify results for depression but only reported that they found no significant treatment effect of bupropion on this outcome variable. </p> </section> <section id="CD009504-sec-0104"> <p><b>E. Anxiety</b></p> <p>Two studies (184 participants) reported the mean change from baseline for anxiety using Hamiliton Anxiety Rating Scale (HAM‐A; <a href="./references#CD009504-bbs2-0067" title="MaierW , BullerR , PhilippM , HeuserI . The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. Journal of Affective Disorders1988;14(1):61‐8. [PUBMED: 2963053] ">Maier 1988</a>) (<a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>). The pooled, fixed‐effect MD between bupropion and placebo was 0.36 (‐0.72 to 1.43, I<sup>2</sup> = 0%; see <a href="./references#CD009504-fig-0012" title="">Analysis 1.6</a>). </p> <p><a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a> did not quantify results for anxiety but only reported that they found no significant treatment effect of bupropion on this outcome variable. </p> </section> </section> <section id="CD009504-sec-0105"> <h6 class="title">2. Adverse events</h6> <section id="CD009504-sec-0106"> <p><b>A. Proportion of participants withdrawn due to any somatic adverse event</b></p> <p>The reasons for withdrawal were typically not reported and therefore it was not possible to analyse the number of participants who withdrew due to somatic adverse events. </p> </section> <section id="CD009504-sec-0107"> <p><b>B. Proportion of participants withdrawn due to any psychiatric adverse event</b></p> <p>The reasons for withdrawal were typically not reported and therefore it was not possible to analyse the number of participants who withdrew due to psychiatric adverse events. </p> </section> </section> </section> <section id="CD009504-sec-0108"> <h5 class="title">Other adverse effect outcomes</h5> <p>As adverse effects were sparsely reported in the studies, we added analyses on related outcomes that were reported, which were: the retention rate, the number of participants that lowered their dose due to adverse effects, and the number of participants with at least one adverse effect (see <a href="#CD009504-sec-0154">Differences between protocol and review</a>). </p> <p>Five studies (352 participants) reported retention rates (number of participants completing the study). The pooled, fixed‐effect RR for completing the treatment was 0.96 (95% CI 0.87 to 1.06, I<sup>2</sup> = 0%; see <a href="./references#CD009504-fig-0013" title="">Analysis 1.7</a>). </p> <p>Two studies (104 participants) reported on the number of participants that lowered their dose due to adverse effects (<a href="./references#CD009504-bbs2-0003" title="LevinFR , EvansSM , BrooksDJ , KalbagAS , GarawiF , NunesEV . Treatment of methadone‐maintained patients with adult ADHD: double‐blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence2006;81(2):137‐48. [DOI: 10.1016/j.drugalcdep.2005.06.012; PUBMED: 16102908] ">Levin 2006</a>; <a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>). The pooled, fixed‐effect RR was 1.86 (95% CI 0.57 to 6.10, I<sup>2</sup> = 0%; see <a href="./references#CD009504-fig-0014" title="">Analysis 1.8</a>), indicating that participants on bupropion were more likely to lower their dose compared to those on placebo. </p> <p>Three studies (227 participants) reported on the number of participants with at least one adverse effect (<a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>; <a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>). The pooled, fixed‐effect RR was 1.14 (95% CI 0.95 to 1.37, I<sup>2</sup> = 0%, see <a href="./references#CD009504-fig-0015" title="">Analysis 1.9</a>). </p> <p>It was not possible to evaluate the impact of adverse effects. Such details were reported sparsely and used different terminology. <a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a> and <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a> stated that no serious adverse effects occurred. <a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a> noted only mild and moderate adverse effects, and <a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a> reported that “there were no significant adverse effects". </p> </section> <section id="CD009504-sec-0109"> <h5 class="title">Sensitivity analyses</h5> <p>The severity of ADHD was assessed by the clinician in three studies (<a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>; <a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>). We pooled in a meta‐analysis data from two studies (<a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>; <a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>), both of which reported final severity scores (see <a href="./references#CD009504-fig-0016" title="">Analysis 2.1</a>; 87 participants). This sensitivity analysis showed a non‐significant result for the severity of ADHD when pooling only studies using clinician‐rated scales (see also <a href="#CD009504-tbl-0004">Table 3</a>). </p> <div class="table" id="CD009504-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Results sensitivity analysis</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fixed‐effect model</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies excluding psychiatric comorbidity (fixed‐effect model)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Random‐effects model</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies using clinician‐rated scales</b> </p> <p><b>(fixed‐effect model)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severity of ADHD symptoms</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.50 (95% CI ‐0.86 to ‐0.15), 129 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.55 (95% CI ‐0.98 to ‐0.12), 89 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.50 (95% CI ‐0.86 to ‐0.15), 129 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.36 (95% CI ‐0.79 to 0.07), 87 participants</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion with significant clinical improvement</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.50 (95% CI 1.13 to 1.99), 315 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.58 (95% CI 1.06 to 2.35), 209 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.48 (95% CI 1.05 to 2.11), 315 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion with at least 1 or 2 on CGI</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.78 (95% CI 1.27 to 2.50), 337 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.06 (95% CI 1.34 to 3.16), 231 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.79 (95% CI 1.02 to 3.14), 337 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: number of patients withdrawn</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20 (95% CI 0.35 to 4.10), 253 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.42 (95% CI 0.49 to 12.01), 187 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.85 (95% CI 0.07 to 9.77), 253 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADHD: attention deficit hyperactivity disorder<br/> CGI: Clinical Global Impression scale<br/> CI: confidence interval<br/> N/A: not applicable<br/> RR: risk ratio<br/> SMD: standardised mean difference </p> </div> </div> <p>We were unable to pool the data from two studies, which assessed the severity of ADHD using patient‐rated scales, as one reported final values (<a href="./references#CD009504-bbs2-0001" title="HamediM , MohammadiM , GhaleihaA , KeshavarziZ , JafariniaM , KeramatfarR , et al. Bupropion in adults with attention‐deficit/hyperactivity disorder: a randomized double‐blinded study. Acta Medica Iranica2014;52(9):675‐80. [PUBMED: 25325205] ">Hamedi 2014</a>) and the other reported mean change from baseline (<a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>). </p> <p>We performed sensitivity analyses on studies that excluded participants with psychiatric comorbidity (<a href="./references#CD009504-bbs2-0001" title="HamediM , MohammadiM , GhaleihaA , KeshavarziZ , JafariniaM , KeramatfarR , et al. Bupropion in adults with attention‐deficit/hyperactivity disorder: a randomized double‐blinded study. Acta Medica Iranica2014;52(9):675‐80. [PUBMED: 25325205] ">Hamedi 2014</a>; <a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>; <a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>); see <a href="./references#CD009504-fig-0017" title="">Analysis 2.2</a>, <a href="./references#CD009504-fig-0018" title="">Analysis 2.3</a>, <a href="./references#CD009504-fig-0019" title="">Analysis 2.4</a>; <a href="./references#CD009504-fig-0020" title="">Analysis 2.5</a>. The results, which are very similar to our overall results, are presented in <a href="#CD009504-tbl-0004">Table 3</a> for ease of comparison. </p> <p>Finally, we performed sensitivity analyses using random‐effects models. The results were similar to those obtained when using fixed‐effect models. <a href="#CD009504-tbl-0004">Table 3</a> presents the results of both models. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009504-sec-0110" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009504-sec-0110"></div> <section id="CD009504-sec-0111"> <h3 class="title" id="CD009504-sec-0111">Summary of main results</h3> <p>Efficacy of pharmacotherapy in treating ADHD symptoms has generally been considerable, with at least three‐quarters of individuals reported to benefit from pharmacotherapy, typically in the form of stimulants. While stimulant medications are the primary pharmacological treatment for ADHD during a lifespan, a subset of people with ADHD do not experience any benefit from stimulants or cannot tolerate effective stimulant doses (<a href="./references#CD009504-bbs2-0109" title="WaxmonskyJG . Nonstimulant therapies for attention‐deficit hyperactivity disorder (ADHD) in children and adults. Essential Psychopharmacology2005;6(5):262‐76. [PUBMED: 16222911] ">Waxmonsky 2005</a>). We analysed the use of a nonstimulant psychopharmacologic agent, bupropion, to treat ADHD in adults. </p> <p>Overall, the results of this review suggest a possible benefit of bupropion on core ADHD symptoms. All pooled point estimates of the three primary efficacy outcomes showed benefit for bupropion when compared to placebo. Groups that received bupropion had lower severity of ADHD symptoms, and more participants achieved a significant clinical improvement or improved at least one or two points on the CGI scale. The evidence is of low quality, mainly due to methodological limitations, poor reporting and a lack of precision, meaning that there is uncertainty in these results. </p> <p>We also found low‐quality evidence that suggests that the tolerability of bupropion is similar to that of placebo. Based on three studies, there was no difference between those given bupropion and those given placebo as regards risk of withdrawal from the study due to adverse effects. Also, we found no difference between bupropion and placebo for the other tolerability outcomes (i.e. overall retention rates, and the number of participants that lowered their dose due to adverse effects). </p> </section> <section id="CD009504-sec-0112"> <h3 class="title" id="CD009504-sec-0112">Overall completeness and applicability of evidence</h3> <p>We conducted this Cochrane Review to ascertain whether bupropion is a viable alternative for adults with ADHD who do not experience symptom relief or cannot tolerate the side effects of first‐line agents such as stimulants. Our findings correlate with the recommendations reflected in major international guidelines (<a href="./references#CD009504-bbs2-0022" title="Bolea‐AlamañacB , NuttDJ , AdamouM , AshersonP , BazireS , CoghillD , et al. Evidence‐based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology2014;28(3):179‐203. [DOI: 10.1177/0269881113519509; PUBMED: 24526134] ">Bolea‐Alamañac 2014</a>; <a href="./references#CD009504-bbs2-0079" title="National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults (NICE guidelines CG72). www.nice.org.uk/guidance/cg72 (accessed 19 May 2015). ">NICE 2008</a>), where the effectiveness of bupropion reaches a Ib level and is considered a second‐ or third‐line medication, for use in tertiary care services. It should be noted that bupropion is an unlicensed medication for the treatment of ADHD, so its use is considered off‐label. </p> <p>This review found only six RCTs. Of these, five had small samples, ranging from 11 to 33 participants in each group. We therefore cannot exclude a type II error, meaning that we cannot conclude that bupropion is not effective. Only short‐term outcomes, from six to 10 weeks, were reported and dose regimens were not uniform across the studies. We therefore cannot confirm that efficacy and safety outcomes apply in the long term in this patient group, where chronic exposure to medication is the rule rather than the exception. Four studies excluded participants with psychiatric comorbidity and one study (<a href="./references#CD009504-bbs2-0003" title="LevinFR , EvansSM , BrooksDJ , KalbagAS , GarawiF , NunesEV . Treatment of methadone‐maintained patients with adult ADHD: double‐blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence2006;81(2):137‐48. [DOI: 10.1016/j.drugalcdep.2005.06.012; PUBMED: 16102908] ">Levin 2006</a>) included methadone‐maintained participants with ADHD. The exclusion of comorbid disorders in these studies is in contrast with the very high prevalence of associated disorders encountered in real‐world practice. A substantial number of participants with ADHD suffer from mood, anxiety, developmental, and substance abuse disorders. The effects on daily functioning are ambiguous in most studies. Adverse effects were not always systematically evaluated. The methodological shortcomings, as described above, limit the generalisability of the results. </p> <p>The predominance of white participants limits the generalisability of the findings. Although none of the studies remarked on ethnic effects, there is some evidence that metabolism of bupropion differs across ethnic groups. In humans, bupropion is metabolised by cytochrome P450 2B6 (CYP‐2B6) to its active metabolite. <a href="./references#CD009504-bbs2-0001" title="HamediM , MohammadiM , GhaleihaA , KeshavarziZ , JafariniaM , KeramatfarR , et al. Bupropion in adults with attention‐deficit/hyperactivity disorder: a randomized double‐blinded study. Acta Medica Iranica2014;52(9):675‐80. [PUBMED: 25325205] ">Hamedi 2014</a> administered a maximum of 150 mg a day because of side effects in their study population, which is a low dose compared to other trials. They hypothesised that genetic polymorphism across different ethnic groups with regard to CYP‐2B6 activity may explain the differential response or vulnerability to side effects amongst different ethnic populations. Striking differences among different ethnic groups were observed, whereby CYP2B6 activity was 3.6‐ and five‐fold higher in Hispanic women than in white or African‐American women (<a href="./references#CD009504-bbs2-0063" title="LambaV , LambaJ , YasudaK , StromS , DavilaJ , HancockML , et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (Constitutive Androstane Receptor) expression. Journal of Pharmacology and Experimental Therapeutics2003;307(3):906‐22. [DOI: 10.1124/jpet.103.054866; PUBMED: 14551287] ">Lamba 2003</a>). Evidence of dependence of CYP2B6 activity on ethnicity or genotype‐by‐ethnicity interactions was not detected in women. These results suggest that the CYP2B6 genotype is the most important variable for predicting the level of CYP2B6 activity in women, when measured by the metabolism of bupropion (<a href="./references#CD009504-bbs2-0060" title="IlicK , HawkeRL , ThirumaranRK , SchuetzEG , HullJH , KashubaAD , et al. The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans. Drug Metabolism and Disposition2013;41(3):575‐81. [DOI: 10.1124/dmd.112.048108; PMC4162003] ">Ilic 2013</a>). </p> <p>Sensitivity analyses suggested that the person who completes the scale on the severity of ADHD influences this outcome. We found no difference between bupropion and placebo measured using clinician‐rated scales. In contrast, we observed a small difference between the two groups when pooling clinician‐rated and self‐rated scales. There is ample knowledge on the difference between self‐rated and clinician‐rated scales for ADHD. <a href="./references#CD009504-bbs2-0008" title="AdlerLA , FaraoneSV , SpencerTJ , MichelsonD , ReimherrFW , GlattSJ , et al. The reliability and validity of self‐ and investigator ratings of ADHD in adults. Journal of Attention Disorders2008;11(6):711‐9. [DOI: 10.1177/1087054707308503; PUBMED: 18025250] ">Adler 2008</a> found suggestive evidence that clinician‐rated ADHD scores better predict the treatment effect. This does not match our results. However, our pooled result was based on only three small studies. Future studies should examine this topic in more detail. </p> <p>This review identified studies up to February 2017. ADHD criteria have changed markedly over this period, and, in particular, the prevalence and comorbidity profile of this population has shifted significantly with the adoption of the <i>DSM‐5</i> in 2013. The <i>DSM‐5</i> changes have the potential for increases in ADHD prevalence and concomitant psychostimulant treatment. For example, raising the age of onset, combined with the requirement to show only symptoms in the past (rather than impairment), may increase levels of diagnosis (<a href="./references#CD009504-bbs2-0092" title="SibleyMH , WaxmonskyJG , RobbJA , PelhamWE . Implications of changes for the field: ADHD. Journal of Learning Disabilities2013;46(1):34‐42. [DOI: 10.1177/0022219412464350; PUBMED: 23128456] ">Sibley 2013</a>). Close analysis shows that the changes in the <i>DSM‐5</i> are more than just a tweak in terminology. The result is likely to be a growth in levels of diagnosis and increased demands on clinical, health and education professionals (<a href="./references#CD009504-bbs2-0087" title="ProsserB , ReidR . The DSM‐5 changes and ADHD: more than a tweak of terms. The Australian and New Zealand Journal of Psychiatry2013;47(12):1196‐7. [DOI: 10.1177/0004867413509695; PUBMED: 24159050] ">Prosser 2013</a>). The consequences of recent changes in diagnostic practice arising from the use of <i>DSM‐5</i> and the effects of these on the generalisability of our findings are largely unknown. Future studies testing the effect of this criterion change in large population samples are therefore needed (<a href="./references#CD009504-bbs2-0071" title="MatteB , RohdeLA , TurnerJB , FisherPW , ShenS , BauCH , et al. Reliability and validity of proposed DSM‐5 ADHD symptoms in a clinical sample of adults. Journal of Neuropsychiatry and Clinical Neurosciences2015;27(3):228‐36. [DOI: 10.1176/appi.neuropsych.13060137; PUBMED: 26067434] ">Matte 2015</a>). </p> <p>People with ADHD are at risk for comorbidities such as depression. Bupropion is an anti‐depressant and, if the drug is shown to be effective, we do not know the working mechanism in people with ADHD. Although some evidence suggests that bupropion may be useful in adolescents with a dual diagnosis of ADHD and depression (<a href="./references#CD009504-bbs2-0028" title="DavissWB , BentivoglioP , RacusinR , BrownKM , BosticJQ , WileyL . Bupropion sustained release in adolescents with comorbid attention‐deficit/hyperactivity disorder and depression. Journal of the American Academy of Child Adolescent Psychiatry2001;40(3):307‐14. [DOI: 10.1097/00004583‐200103000‐00010; PUBMED: 11288772] ">Daviss 2001</a>), no studies of good quality have addressed the issue whether bupropion alleviates ADHD symptoms directly or whether it works indirectly through its antidepressant effects. </p> <p>Another limitation of the studies has been the focus on ADHD symptoms as a measure of efficacy, as the effects of medication in ADHD is typically assessed using symptoms scales. However, cognitive benefits may be more important to patients than symptoms scales. The effects of bupropion on cognition in people with ADHD have yet to assessed directly. Several stimulants trials have demonstrate that when used at low and clinically‐relevant doses, psychostimulants improve prefrontal cortex (PFC)‐dependent behavioural or cognitive processes in people with and without ADHD (<a href="./references#CD009504-bbs2-0072" title="MehtaMA , OwenAM , SahakianBJ , MavaddatN , PickardJD , RobbinsTW . Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. Journal of Neuroscience2000;20(6):RC65. [PUBMED: 10704519] ">Mehta 2000</a>; <a href="./references#CD009504-bbs2-0088" title="RapoportJL , Inoff‐GermainG . Responses to methylphenidate in Attention‐Deficit/Hyperactivity Disorder and normal children: update 2002. Journal of Attention Disorders2002;6(Suppl 1):S57‐60. [PUBMED: 12685519] ">Rapoport 2002</a>). One study found that bupropion improved attention, as measured by the CPT( Continuous performance Test), in people with schizophrenia (<a href="./references#CD009504-bbs2-0035" title="EvinsAE , DeckersbachT , CatherC , FreudenreichO , CulhaneMA , HendersonDC , et al. Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. Journal of Clinical Psychiatry2005;66(9):1184‐90. [PUBMED: 16187778] ">Evins 2005</a>), while another found that bupropion partially improved visual memory and mental processing speed performance in people with a major depressive disorder (<a href="./references#CD009504-bbs2-0019" title="BidwellLC , McClernonFJ , KollinsSH . Cognitive enhancers for the treatment of ADHD. Pharmacology, Biochemistry, and Behavior2011;99(2):262‐74. [DOI: 10.1016/j.pbb.2011.05.002; PMC3353150; PUBMED: 21596055] ">Bidwell 2011</a>; <a href="./references#CD009504-bbs2-0054" title="Herrera‐GuzmánI , Gudayol‐FerréE , Lira‐MandujanoJ , Herrera‐AbarcaJ , Herrera‐GuzmánD , Montoya‐PérezK , et al. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder. Psychiatry Research2008;160(1):72‐82. [DOI: 10.1016/j.psychres.2007.04.012; PUBMED: 18501971] ">Herrera‐Guzmán 2008</a>). Future studies should incorporate more measures of functional impairment. </p> <p>Based on expert opinion, guidelines recommend consideration of the use of bupropion, if the risk of stimulant abuse is high (<a href="./references#CD009504-bbs2-0022" title="Bolea‐AlamañacB , NuttDJ , AdamouM , AshersonP , BazireS , CoghillD , et al. Evidence‐based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology2014;28(3):179‐203. [DOI: 10.1177/0269881113519509; PUBMED: 24526134] ">Bolea‐Alamañac 2014</a>). Whether there is a therapeutic niche for bupropion as a first‐line treatment for ADHD and comorbid substance abuse cannot be extrapolated from this review. Drug dependence is frequent in people with ADHD. A systematic review by <a href="./references#CD009504-bbs2-0027" title="CunillR , CastellsX , TobiasA , CapellàD . Pharmacological treatment of attention deficit hyperactivity disorder with co‐morbid drug dependence. Journal of Psychopharmacology2015;29(1):15‐23. [DOI: 10.1177/0269881114544777; PUBMED: 25142405] ">Cunill 2015</a> showed that pharmacological nterventions (including bupropion) improved ADHD symptoms, but noted no beneficial effect on drug abstinence or on treatment discontinuation. The strength of the recommendation of pharmacological treatment for co‐occurring ADHD and substance use disorder was therefore regarded as modest. </p> </section> <section id="CD009504-sec-0113"> <h3 class="title" id="CD009504-sec-0113">Quality of the evidence</h3> <p>We judged the overall quality of evidence in this review to be low. Reasons for downgrading were serious risk of bias and serious imprecision. </p> <p>We considered the included studies to have serious risks of bias. The main reason was poor reporting, which meant that it was not possible to judge whether studies were free of important biases. All included studies were RCTs but none described the procedures used for sequence generation and only one for allocation concealment. All studies were reported as double‐blinded, but the methods for blinding were poorly described by study authors. Only two studies reported that they used identical‐looking placebo tablets, which would imply that participants were blinded. Only one study reported that outcome assessors were blinded. Blinding is important to prevent bias for subjective outcomes such as the CGI scale (<a href="./references#CD009504-bbs2-0080" title="National Institute of Mental Health. CGI (Clinical Global Impression Scale). Psychopharmacology Bulletin1985;21:839‐44. ">NIMH 1984</a>), and adverse effects. As all outcomes in this review are subjective, lack of blinding could have affected the results of the studies. We judged none of the studies to be free of selective reporting, as the protocol was not available for most of them. Finally, none of the studies used a true intention‐to‐treat analysis. Typically, the numbers of participants analysed were not reported or a modified intention‐to‐treat analysis was used, including a subset of all randomised participants. Participants who are randomised but not included in analyses are likely to differ from those who are included in an analysis, and this may potentially lead to bias. The limitations in study design were one of the reasons to downgrade the level of evidence (see <a href="./full#CD009504-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>We judged results for all outcomes to be imprecise. Of our six included studies, five had a sample size of fewer than 50. There were fewer than 300 events for all dichotomous outcomes, which does not meet the OIS criterion as suggested by the GRADE Handbook (<a href="./references#CD009504-bbs2-0091" title="SchünemannH , BrożekJ , GuyattG , OxmanA , GRADE Working Group. GRADE handbook for grading quality of evidence and strength of recommendations. www.guidelinedevelopment.org/handbook. (accessed prior to 30 May 2017). ">Schünemann 2013</a>). This imprecision due to the small number of events is a major limitation that hampers the generalisability of these results. We found no limitations with respect to the consistency of effect or indirectness. For each outcome, we judged the results to be consistent and direct. </p> <p>Four of the six studies were sponsored by industry, but the effects of funding on study results were not clear. For example, there may be a difference between trials that were performed by industry versus trials that were performed by an investigator. From personal correspondence, we know that two studies were investigator‐driven (<a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a>; <a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>); this is unclear for all other studies. The two remaining studies were publicly funded, though the lead author in one of these studies was a consultant for several pharmaceutical companies and also received investigator‐driven funding from two companies, however none of these companies manufacture bupropion. We therefore cannot make assumptions on the effects of funding on the conclusions of the review. </p> </section> <section id="CD009504-sec-0114"> <h3 class="title" id="CD009504-sec-0114">Potential biases in the review process</h3> <p>We conducted a comprehensive search of the literature and did not apply any restrictions by language or publication status. However, we cannot be sure that we found all relevant studies. We were not able to statistically assess the risk of publication bias due to the small number of studies, however some characteristics of this review may indicate a potential risk of publication bias. For example, four studies were sponsored by pharmaceutical companies that produce bupropion, and the lead author of one of the two publicly‐funded studies was paid by industry (although not by the manufacturers of bupropion) for research activities. <a href="./references#CD009504-bbs2-0066" title="LexchinJ , BeroLA , DjulbegovicB , ClarkO . Pharmaceutical industry sponsorship and research outcome and quality: a systematic review. BMJ2003;326(7400):1167‐70. [DOI: 10.1136/bmj.326.7400.1167; PMC156458; PUBMED: 12775614] ">Lexchin 2003</a> investigated whether the quality of the methods in studies funded by pharmaceutical companies differs from that in other studies and concluded that "studies sponsored by pharmaceutical companies were more likely to have outcomes favouring the sponsor than were studies with other sponsors". One of the explanations that they provided for these results was publication bias. We are not able to confirm or refute this conclusion, as the majority of our included studies were sponsored by industry. Another indication of publication bias was the lack of studies with negative results, which may be due to sampling variance even if there is in general a positive effect. <a href="./references#CD009504-bbs2-0059" title="HopewellS , LoudonK , ClarkeMJ , OxmanAD , DickersinK . Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.MR000006.pub3] ">Hopewell 2009</a> found that studies with positive results are more likely to be published than studies with negative results. </p> <p>The included studies in this review do not provide an adequate basis for the assessment of adverse effects. The results of this review, with respect to the adverse effects, may therefore underestimate the adverse effects in real life. The duration of trials was six to 10 weeks, and provided no information on longer‐term effects. The studies do not provide a clear picture of the severity of the adverse effects. We anticipated analysing the proportion of participants that withdrew due to psychiatric or somatic adverse effects, but causes of withdrawal were not reported. During data extraction, we noted two trials reporting on ‘the number of participants that lowered their dose due to adverse events’. This outcome implies an impact or severity of adverse effects because participants will lower their dose when adverse effects outweigh the benefits gained from bupropion. Consequently, we added this outcome to this review post hoc (see <a href="#CD009504-sec-0154">Differences between protocol and review</a>). Future reviews should try to capture the impact or severity of adverse effects of bupropion on the participant. </p> </section> <section id="CD009504-sec-0115"> <h3 class="title" id="CD009504-sec-0115">Agreements and disagreements with other studies or reviews</h3> <p>Two previous systematic reviews have assessed the effects of bupropion for adult ADHD. <a href="./references#CD009504-bbs2-0039" title="FaraoneSV , GlattSJ . A comparison of the efficacy of medications for adult attention‐deficit/hyperactivity disorder using meta‐analysis of effect sizes. Journal of Clinical Psychiatry2010;71(6):754‐63. [DOI: 10.4088/JCP.08m04902pur; PUBMED: 20051220] ">Faraone 2010</a> estimated effect sizes of different medications for adult ADHD. They included double‐blinded, placebo‐controlled studies of ADHD in adults that presented the means and SDs of either change or endpoint scores for intervention and placebo groups. Out of 18 records, they found three studies that evaluated bupropion versus placebo (<a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a>; <a href="./references#CD009504-bbs2-0005" title="WilensTE , SpencerTJ , BiedermanJ , GirardK , DoyleR , PrinceJ , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry2001;158(2):282‐8. [DOI: 10.1176/appi.ajp.158.2.282; PUBMED: 11156812] ">Wilens 2001</a>; <a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a>). Whilst they did not provide an estimate of effects for the thee studies of bupropion, they estimated the number needed to treat for an additional beneficial outcome (NNTB) to be approximately 4.5 for bupropion. </p> <p><a href="./references#CD009504-bbs2-0068" title="ManeetonN , ManeetonB , SrisurapanontM , MartinSD . Bupropion for adults with attention‐deficit hyperactivity disorder: meta‐analysis of randomized, placebo‐controlled trials. Psychiatry and Clinical Neurosciences2011;65(7):611‐7. [DOI: 10.1111/j.1440‐1819.2011.02264.x; PUBMED: 22176279] ">Maneeton 2011</a> aimed to systematically review the efficacy, acceptability, and tolerability of bupropion compared to placebo for adults with ADHD. They included five trials also included in our review and reached similar conclusions. There are some differences between their review and ours in the way that results are included in the analysis. For example, we set higher standards for methodological quality, concluding that for most items reporting was incomplete to make a robust assessment, whereas <a href="./references#CD009504-bbs2-0068" title="ManeetonN , ManeetonB , SrisurapanontM , MartinSD . Bupropion for adults with attention‐deficit hyperactivity disorder: meta‐analysis of randomized, placebo‐controlled trials. Psychiatry and Clinical Neurosciences2011;65(7):611‐7. [DOI: 10.1111/j.1440‐1819.2011.02264.x; PUBMED: 22176279] ">Maneeton 2011</a> judged all studies to be at low risk of bias. The authors concluded that evidence suggests that bupropion is effective and safe for adults with ADHD. Although the conclusions are similar to our review, their review lacks any caution with respect to their conclusion due to small studies sizes and poor reporting of study quality. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009504-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/urn:x-wiley:14651858:media:CD009504:CD009504-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_t/tCD009504-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009504-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/full#CD009504-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009504-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/urn:x-wiley:14651858:media:CD009504:CD009504-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_t/tCD009504-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD009504-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/full#CD009504-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009504-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/urn:x-wiley:14651858:media:CD009504:CD009504-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_t/tCD009504-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Bupropion versus placebo, outcome: 1.1 Severity of ADHD (at study completion)." data-id="CD009504-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Bupropion versus placebo, outcome: 1.1 Severity of ADHD (at study completion). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/full#CD009504-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009504-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/urn:x-wiley:14651858:media:CD009504:CD009504-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_t/tCD009504-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Bupropion vs placebo, outcome: 1.1 Achievement of significant clinical improvement (% participants)." data-id="CD009504-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Bupropion vs placebo, outcome: 1.1 Achievement of significant clinical improvement (% participants). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/full#CD009504-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009504-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/urn:x-wiley:14651858:media:CD009504:CD009504-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_t/tCD009504-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Bupropion vs placebo, outcome: 1.3 Clinical Global Impression (CGI) ‐ improvement scale (% participants achieving at least 1 or 2 on CGI)." data-id="CD009504-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Bupropion vs placebo, outcome: 1.3 Clinical Global Impression (CGI) ‐ improvement scale (% participants achieving at least 1 or 2 on CGI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/full#CD009504-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009504-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/urn:x-wiley:14651858:media:CD009504:CD009504-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_t/tCD009504-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Bupropion versus placebo, outcome: 1.4 Number of participants withdrawn due to adverse events." data-id="CD009504-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Bupropion versus placebo, outcome: 1.4 Number of participants withdrawn due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/full#CD009504-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009504-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/urn:x-wiley:14651858:media:CD009504:CD009504-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_t/tCD009504-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bupropion versus placebo, Outcome 1 Severity of ADHD (at study completion)." data-id="CD009504-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Bupropion versus placebo, Outcome 1 Severity of ADHD (at study completion).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/references#CD009504-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009504-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/urn:x-wiley:14651858:media:CD009504:CD009504-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_t/tCD009504-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bupropion versus placebo, Outcome 2 Achievement of significant clinical improvement (% participants)." data-id="CD009504-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Bupropion versus placebo, Outcome 2 Achievement of significant clinical improvement (% participants). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/references#CD009504-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009504-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/urn:x-wiley:14651858:media:CD009504:CD009504-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_t/tCD009504-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bupropion versus placebo, Outcome 3 Clinical Global Impression (CGI) ‐ Improvement scale (% participants achieving at least one or two on CGI)." data-id="CD009504-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Bupropion versus placebo, Outcome 3 Clinical Global Impression (CGI) ‐ Improvement scale (% participants achieving at least one or two on CGI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/references#CD009504-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009504-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/urn:x-wiley:14651858:media:CD009504:CD009504-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_t/tCD009504-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bupropion versus placebo, Outcome 4 Number of participants withdrawn due to adverse events." data-id="CD009504-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Bupropion versus placebo, Outcome 4 Number of participants withdrawn due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/references#CD009504-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009504-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/urn:x-wiley:14651858:media:CD009504:CD009504-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_t/tCD009504-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bupropion versus placebo, Outcome 5 Depressive symptoms (change from baseline to study completion)." data-id="CD009504-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Bupropion versus placebo, Outcome 5 Depressive symptoms (change from baseline to study completion). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/references#CD009504-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009504-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/urn:x-wiley:14651858:media:CD009504:CD009504-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_t/tCD009504-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bupropion versus placebo, Outcome 6 Anxiety symptoms (change from baseline to study completion)." data-id="CD009504-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Bupropion versus placebo, Outcome 6 Anxiety symptoms (change from baseline to study completion). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/references#CD009504-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009504-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/urn:x-wiley:14651858:media:CD009504:CD009504-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_t/tCD009504-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bupropion versus placebo, Outcome 7 Retention rate (number of patients completing study)." data-id="CD009504-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Bupropion versus placebo, Outcome 7 Retention rate (number of patients completing study). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/references#CD009504-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009504-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/urn:x-wiley:14651858:media:CD009504:CD009504-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_t/tCD009504-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bupropion versus placebo, Outcome 8 Number of participants that lowered their dose due to adverse events." data-id="CD009504-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Bupropion versus placebo, Outcome 8 Number of participants that lowered their dose due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/references#CD009504-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009504-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/urn:x-wiley:14651858:media:CD009504:CD009504-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_t/tCD009504-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bupropion versus placebo, Outcome 9 Number of participants with at least one adverse event." data-id="CD009504-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Bupropion versus placebo, Outcome 9 Number of participants with at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/references#CD009504-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009504-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/urn:x-wiley:14651858:media:CD009504:CD009504-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_t/tCD009504-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bupropion versus placebo (sensitivity analyses), Outcome 1 Severity of ADHD (at study completion) ‐ clinician rated." data-id="CD009504-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Bupropion versus placebo (sensitivity analyses), Outcome 1 Severity of ADHD (at study completion) ‐ clinician rated. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/references#CD009504-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009504-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/urn:x-wiley:14651858:media:CD009504:CD009504-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_t/tCD009504-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bupropion versus placebo (sensitivity analyses), Outcome 2 Severity if ADHD (at study completion) ‐ studies that exclude psychiatric comorbidity." data-id="CD009504-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Bupropion versus placebo (sensitivity analyses), Outcome 2 Severity if ADHD (at study completion) ‐ studies that exclude psychiatric comorbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/references#CD009504-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009504-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/urn:x-wiley:14651858:media:CD009504:CD009504-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_t/tCD009504-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bupropion versus placebo (sensitivity analyses), Outcome 3 Achievement of significant clinical improvement (% participants) ‐ studies that exclude psychiatric comorbidity." data-id="CD009504-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Bupropion versus placebo (sensitivity analyses), Outcome 3 Achievement of significant clinical improvement (% participants) ‐ studies that exclude psychiatric comorbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/references#CD009504-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009504-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/urn:x-wiley:14651858:media:CD009504:CD009504-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_t/tCD009504-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bupropion versus placebo (sensitivity analyses), Outcome 4 CGI ‐ Improvement (% participants achieving at least one or two on CGI) ‐ studies that exclude psychiatric comorbidity." data-id="CD009504-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Bupropion versus placebo (sensitivity analyses), Outcome 4 CGI ‐ Improvement (% participants achieving at least one or two on CGI) ‐ studies that exclude psychiatric comorbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/references#CD009504-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009504-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/urn:x-wiley:14651858:media:CD009504:CD009504-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_t/tCD009504-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bupropion versus placebo (sensitivity analyses), Outcome 5 Number of participants withdrawn due to adverse events ‐ studies that exclude psychiatric comorbidity." data-id="CD009504-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Bupropion versus placebo (sensitivity analyses), Outcome 5 Number of participants withdrawn due to adverse events ‐ studies that exclude psychiatric comorbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/references#CD009504-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/media/CDSR/CD009504/image_n/nCD009504-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009504-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Bupropion compared with placebo for adult ADHD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Participant or population:</b> Adults with ADHD </p> <p><b>Settings:</b> Ambulant care </p> <p><b>Intervention:</b> Bupropion </p> <p><b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Bupropion</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severity of ADHD (at study completion)</b> </p> <p>WRAADDS scale (0 to 28), ADHD‐RS scale (0 to 54) or CAARS scale (0 to 48). On all scales, a higher score equates to more symptoms </p> <p>(at 6 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score for severity of ADHD ranged across control groups from 14.70 (WRAADDS) to 23.80 (ADHD‐RS) and 34.43 (CAARS) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised mean score for severity of ADHD in the intervention groups was on average 0.50 <b>lower</b> (0.86 lower to 0.15 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Achievement of significant clinical improvement (% participants)</b> </p> <p>(at 6 to 10 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>212 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>318 per 1000</b> <br/> (from 240 to 422) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.50</b> (1.13 to 1.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>315<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CGI ‐ Improvement scale (% participants achieving at least 1 or 2 on CGI)</b> </p> <p>(at 6 to 10 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>395 per 1000</b> </p> <p>(from 282 to 555)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.78</b> (1.27 to 2.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>337<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants withdrawn due to adverse events</b> </p> <p>(at 6 to 10 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>73 per 1000</b> <br/> (from 21 to 250) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.20</b> (0.35 to 4.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> was the median control group risk across studies. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ADHD:</b> attention deficit hyperactivity disorder; <b>ADHD‐RS:</b> ADHD symptoms rating scale; <b>CAARS:</b> Conners' Adult ADHD Rating Scales; <b>CGI:</b> Clinical Global Impression scale;<b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; <b>WRAADDS:</b> Wender‐Reimherr Adult Attention Deficit Disorder Scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to limitations in study design. Most quality items were poorly reported.<br/> <sup>2</sup>Downagraded by one level due to imprecision. Optimal information size (OIS) not met. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/full#CD009504-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009504-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Methods archived for future updates of this review</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Topic</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Method</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unit of analysis issues</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross‐over trials</b> </p> <p>We will include cross‐over trials. Given the risk of carry‐over effects, we will use data from the first period (before cross‐over) only, and treat these as parallel‐group trials. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Assessment of reporting biases</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We will produce funnel plots (estimated treatment effects against their standard error). We will test funnel plot asymmetry when there are at least 10 studies included in the meta‐analysis. Asymmetry could be due to publication bias, but could also be due to a relationship between trial size and effect size. In the event that we find a relationship, we will examine the clinical diversity of the studies, selection biases and poor methodological quality as alternative explanations to publication bias. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Subgroup analysis and investigation of heterogeneity</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We will perform two subgroup analyses:</p> <p> <ol id="CD009504-list-0007"> <li> <p>Type of drug release formulation: immediate release, sustained release and extended release. </p> </li> <li> <p>Dose: above versus below median dose.</p> </li> </ol> </p> <p>When there are more than 10 studies included in the analyses, we will investigate statistical heterogeneity using meta‐regression (<a href="./references#CD009504-bbs2-0029" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Multiple time points</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We will classify outcomes of all studies based on time of measurement from randomisation: acute (less than 24 hours), short‐term (less than six weeks), medium‐term (six weeks to six months), and long‐term (more than six months). Within each time period, we will include the latest outcome in the meta‐analysis. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sensitivity analysis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We will conduct sensitivity analyses to determine whether findings are sensitive to restricting the analyses to studies judged to be at low risk of bias. In these analyses, we will restrict the analysis to the following: </p> <p> <ol id="CD009504-list-0008"> <li> <p>Studies with low risk of selection bias (associated with sequence generation and allocation concealment). </p> </li> <li> <p>Studies without financial support from the pharmaceutical industry.</p> </li> <li> <p>Studies that used standardised instrument(s) to measure efficacy.</p> </li> <li> <p>Studies without imputed data (see also 'Dealing with missing data').</p> </li> </ol> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Methods archived for future updates of this review</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/full#CD009504-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009504-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Results of individual studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome/scale</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Results for bupropion</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Results for placebo (P value for difference between groups)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009504-bbs2-0002" title="KupermanS [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 07 June 2016. KupermanS , PerryPJ , GaffneyGR , LundBC , Bever‐StilleKA , ArndtS , et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129‐34. [PUBMED: 11791949] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: S Kuperman 05 June 2016. ">Kuperman 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐rated ADHD symptoms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐13.7 (SD 6.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐12.4 (SD 10.6) (P = 0.69)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009504-bbs2-0004" title="ReimherrF [pers comm] . Reply to: Cochrane review [personal communication]. Email to: W Verbeeck 06 June 2016. ReimherrFW , HedgesDW , StrongRE , MarchantBK , WilliamsED . Bupropion SR in adults with ADHD: a short‐term, placebo‐controlled trial. Neuropsychiatric Disease and Treatment2005;1(3):245‐51. [PMC2416755; PUBMED: 18568102] VerbeeckW [pers comm] . Cochrane review [personal communication]. Email to: F Reimherr 05 June 2016. ">Reimherr 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global level of functioning</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean final value at study completion 57.5 (SD 8.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean final value at study completion 56.2 (SD 3.6) (P &gt; 0.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009504-bbs2-0006" title="HudziakJJ , WilensTE , ConnorDF , HaightBR , HorriganJP , HamptonKD , et al. A controlled trial of extended‐release bupropion in adult ADHD. Biological Psychiatry2004;8(Suppl):135S. WilensTE , HaightBR , HorriganJP , HudziakJJ , RosenthalNE , ConnorDF , et al. Bupropion XL in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled study. Biological Psychiatry2005;57(7):793‐801. [DOI: 10.1016/j.biopsych.2005.01.027; PUBMED: 15820237] ">Wilens 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADHD Symptom Checklist (<a href="./references#CD009504-bbs2-0033" title="DuPaulGJ . The ADHD Rating Scale: Normative Data, Reliability, and Validity. Worchester (MA): University of Massachusetts Medical Center, 1990. ">DuPaul 1990</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean difference from baseline ‐12.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean difference ‐6.9 (P &lt; 0.001)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global level of functioning</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change from baseline 7.3 (SD 10.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0 (SD 8.0) (P = 0.035)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>ADHD: attention deficit hyperactivity disorder<br/> ID: identifier<br/> SD: standard deviation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Results of individual studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/full#CD009504-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009504-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Results sensitivity analysis</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fixed‐effect model</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies excluding psychiatric comorbidity (fixed‐effect model)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Random‐effects model</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies using clinician‐rated scales</b> </p> <p><b>(fixed‐effect model)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severity of ADHD symptoms</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.50 (95% CI ‐0.86 to ‐0.15), 129 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.55 (95% CI ‐0.98 to ‐0.12), 89 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.50 (95% CI ‐0.86 to ‐0.15), 129 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.36 (95% CI ‐0.79 to 0.07), 87 participants</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion with significant clinical improvement</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.50 (95% CI 1.13 to 1.99), 315 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.58 (95% CI 1.06 to 2.35), 209 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.48 (95% CI 1.05 to 2.11), 315 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion with at least 1 or 2 on CGI</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.78 (95% CI 1.27 to 2.50), 337 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.06 (95% CI 1.34 to 3.16), 231 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.79 (95% CI 1.02 to 3.14), 337 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: number of patients withdrawn</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20 (95% CI 0.35 to 4.10), 253 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.42 (95% CI 0.49 to 12.01), 187 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.85 (95% CI 0.07 to 9.77), 253 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>ADHD: attention deficit hyperactivity disorder<br/> CGI: Clinical Global Impression scale<br/> CI: confidence interval<br/> N/A: not applicable<br/> RR: risk ratio<br/> SMD: standardised mean difference </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Results sensitivity analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/full#CD009504-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009504-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Bupropion versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Severity of ADHD (at study completion) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐0.86, ‐0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Achievement of significant clinical improvement (% participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [1.13, 1.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinical Global Impression (CGI) ‐ Improvement scale (% participants achieving at least one or two on CGI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>337</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [1.27, 2.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of participants withdrawn due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.35, 4.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Depressive symptoms (change from baseline to study completion) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [‐0.46, 1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Anxiety symptoms (change from baseline to study completion) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [‐0.72, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Retention rate (number of patients completing study) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.87, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Number of participants that lowered their dose due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [0.57, 6.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Number of participants with at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.95, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Bupropion versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/references#CD009504-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009504-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Bupropion versus placebo (sensitivity analyses)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Severity of ADHD (at study completion) ‐ clinician rated <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.36 [‐0.79, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Severity if ADHD (at study completion) ‐ studies that exclude psychiatric comorbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.55 [‐0.98, ‐0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Achievement of significant clinical improvement (% participants) ‐ studies that exclude psychiatric comorbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [1.06, 2.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 CGI ‐ Improvement (% participants achieving at least one or two on CGI) ‐ studies that exclude psychiatric comorbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [1.34, 3.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of participants withdrawn due to adverse events ‐ studies that exclude psychiatric comorbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.42 [0.49, 12.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Bupropion versus placebo (sensitivity analyses)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009504.pub2/references#CD009504-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009504.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD009504-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD009504-note-0008">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009504-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009504-note-0006">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD009504-note-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD009504-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD009504-note-0007">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD009504-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD009504-note-0002">繁體中文</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009504-note-0015">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009504\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009504\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009504\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009504\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009504\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009504\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009504\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009504\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009504\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009504\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009504\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009504\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009504\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009504\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009504\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009504\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009504\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009504\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=wbKFI7vu&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009504.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009504.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009504.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009504.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009504.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719393938"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009504.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719393942"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009504.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918de7ad5f55f55b',t:'MTc0MDcxOTM5NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 